<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Bioinformatics</journal-id>
    <journal-id journal-id-type="iso-abbrev">Bioinformatics</journal-id>
    <journal-id journal-id-type="publisher-id">bioinformatics</journal-id>
    <journal-title-group>
      <journal-title>Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1367-4803</issn>
    <issn pub-type="epub">1367-4811</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10284671</article-id>
    <article-id pub-id-type="pmid">37326978</article-id>
    <article-id pub-id-type="doi">10.1093/bioinformatics/btad381</article-id>
    <article-id pub-id-type="publisher-id">btad381</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Applications Note</subject>
        <subj-group subj-group-type="category-toc-heading">
          <subject>Systems Biology</subject>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI01060</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>GRETTA: an R package for mapping <italic toggle="yes">in silico</italic> genetic interaction and essentiality networks</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3538-4409</contrib-id>
        <name>
          <surname>Takemon</surname>
          <given-names>Yuka</given-names>
        </name>
        <aff><institution>Genome Science and Technology Graduate Program, University of British Columbia</institution>, Vancouver, BC V5Z 4S6, <country country="CA">Canada</country></aff>
        <aff><institution>Michael Smith Laboratories, University of British Columbia</institution>, Vancouver, BC V6T 1Z4, <country country="CA">Canada</country></aff>
        <aff><institution>Canada’s Michael Smith Genome Sciences Centre, BC Cancer Research Institute</institution>, Vancouver, BC V5Z 4S6, <country country="CA">Canada</country></aff>
        <!--ytakemon@bcgsc.ca-->
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7146-7175</contrib-id>
        <name>
          <surname>Marra</surname>
          <given-names>Marco A</given-names>
        </name>
        <aff><institution>Michael Smith Laboratories, University of British Columbia</institution>, Vancouver, BC V6T 1Z4, <country country="CA">Canada</country></aff>
        <aff><institution>Canada’s Michael Smith Genome Sciences Centre, BC Cancer Research Institute</institution>, Vancouver, BC V5Z 4S6, <country country="CA">Canada</country></aff>
        <aff><institution>Department of Medical Genetics, University of British Columbia</institution>, Vancouver, BC V6H 3N1, <country country="CA">Canada</country></aff>
        <!--mmarra@bcgsc.ca-->
        <xref rid="btad381-cor1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Kelso</surname>
          <given-names>Janet</given-names>
        </name>
        <role>Associate Editor</role>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="btad381-cor1">Corresponding author. Michael Smith Laboratories, University of British Columbia, 301-2185 East Mall, Vancouver, BC V6T 1Z4, Canada. E-mail: <email>mmarra@bcgsc.ca</email> (M.A.M.)</corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <month>6</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2023-06-16">
      <day>16</day>
      <month>6</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>16</day>
      <month>6</month>
      <year>2023</year>
    </pub-date>
    <volume>39</volume>
    <issue>6</issue>
    <elocation-id>btad381</elocation-id>
    <history>
      <date date-type="received">
        <day>21</day>
        <month>9</month>
        <year>2022</year>
      </date>
      <date date-type="rev-recd">
        <day>02</day>
        <month>6</month>
        <year>2023</year>
      </date>
      <date date-type="editorial-decision">
        <day>07</day>
        <month>6</month>
        <year>2023</year>
      </date>
      <date date-type="corrected-typeset">
        <day>21</day>
        <month>6</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2023. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2023</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="btad381.pdf"/>
    <abstract>
      <title>Abstract</title>
      <sec id="s1">
        <title>Summary</title>
        <p>Mapping genetic interactions and essentiality networks in human cell lines has been used to identify vulnerabilities of cells carrying specific genetic alterations and to associate novel functions to genes, respectively. <italic toggle="yes">In vitro</italic> and <italic toggle="yes">in vivo</italic> genetic screens to decipher these networks are resource-intensive, limiting the throughput of samples that can be analyzed. In this application note, we provide an R package we call Genetic inteRaction and EssenTiality neTwork mApper (GRETTA). GRETTA is an accessible tool for <italic toggle="yes">in silico</italic> genetic interaction screens and essentiality network analyses using publicly available data, requiring only basic R programming knowledge.</p>
      </sec>
      <sec id="s2">
        <title>Availability and implementation</title>
        <p>The R package, GRETTA, is licensed under GNU General Public License v3.0 and freely available at <ext-link xlink:href="https://github.com/ytakemon/GRETTA" ext-link-type="uri">https://github.com/ytakemon/GRETTA</ext-link> and <ext-link xlink:href="https://doi.org/10.5281/zenodo.6940757" ext-link-type="uri">https://doi.org/10.5281/zenodo.6940757</ext-link>, with documentation and tutorial. A Singularity container is also available at <ext-link xlink:href="https://cloud.sylabs.io/library/ytakemon/gretta/gretta" ext-link-type="uri">https://cloud.sylabs.io/library/ytakemon/gretta/gretta</ext-link>.</p>
      </sec>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Canadian Institutes of Health Research</institution>
            <institution-id institution-id-type="DOI">10.13039/501100000024</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>FDN-143288</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="4"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec>
    <title>1 Introduction</title>
    <p>Genetic perturbation screens, such as CRISPR-Cas9 knockout (KO) screens, have been used to uncover lethal and alleviating genetic interactions (GIs; <xref rid="btad381-B24" ref-type="bibr">Shalem <italic toggle="yes">et al.</italic> 2014</xref>, <xref rid="btad381-B11" ref-type="bibr">Hart <italic toggle="yes">et al.</italic> 2015</xref>, <xref rid="btad381-B27" ref-type="bibr">Wang <italic toggle="yes">et al.</italic> 2017</xref>, <xref rid="btad381-B1" ref-type="bibr">Behan <italic toggle="yes">et al.</italic> 2019</xref>) and essentiality networks to decipher a gene’s functional membership (<xref rid="btad381-B20" ref-type="bibr">Pan <italic toggle="yes">et al.</italic> 2018</xref>, <xref rid="btad381-B26" ref-type="bibr">Wainberg <italic toggle="yes">et al.</italic> 2021</xref>). Two genes are said to share a lethal, or synthetic lethal (SL), GI when the perturbation of both genes together in the same cell impedes cell viability, but perturbation of either gene individually has no impact on viability (<xref rid="btad381-B15" ref-type="bibr">Mani <italic toggle="yes">et al.</italic> 2008</xref>). Conversely, an alleviating GI occurs when the perturbation of two genes leads to a fitness advantage over cells with either gene perturbed individually (<xref rid="btad381-B15" ref-type="bibr">Mani <italic toggle="yes">et al.</italic> 2008</xref>). Lethal GIs of genes mutated in cancers have revealed tumor-specific vulnerabilities that can be therapeutically exploited. Most notable are the lethal GIs between <italic toggle="yes">BRCA1/2</italic> and <italic toggle="yes">PARP1</italic> (<xref rid="btad381-B4" ref-type="bibr">Bryant <italic toggle="yes">et al.</italic> 2005</xref>, <xref rid="btad381-B9" ref-type="bibr">Farmer <italic toggle="yes">et al.</italic> 2005</xref>), which led to the use of PARP inhibitors in BRCA1/2-deficient breast (<xref rid="btad381-B22" ref-type="bibr">Robson <italic toggle="yes">et al.</italic> 2017</xref>, <xref rid="btad381-B23" ref-type="bibr">2019</xref>), ovarian (<xref rid="btad381-B18" ref-type="bibr">Mirza <italic toggle="yes">et al.</italic> 2018</xref>), and prostate cancers (<xref rid="btad381-B21" ref-type="bibr">Ramakrishnan Geethakumari <italic toggle="yes">et al.</italic> 2017</xref>). Essentiality network maps have been utilized to assign novel functions to genes (<xref rid="btad381-B27" ref-type="bibr">Wang <italic toggle="yes">et al.</italic> 2017</xref>, <xref rid="btad381-B14" ref-type="bibr">Kim <italic toggle="yes">et al.</italic> 2019</xref>, <xref rid="btad381-B26" ref-type="bibr">Wainberg <italic toggle="yes">et al.</italic> 2021</xref>, <xref rid="btad381-B20" ref-type="bibr">Pan <italic toggle="yes">et al.</italic> 2018</xref>). Two genes share co-essentiality when perturbation of either gene leads to similar fitness effects in cells. This is interpreted to indicate that the genes may have similar or synergistic functions (<xref rid="btad381-B14" ref-type="bibr">Kim <italic toggle="yes">et al.</italic> 2019</xref>, <xref rid="btad381-B26" ref-type="bibr">Wainberg <italic toggle="yes">et al.</italic> 2021</xref>). In contrast, two genes are antiessential when perturbations in either of them lead to opposite cellular fitness effects. This is interpreted to indicate genes with inhibitory or antagonistic relationships (<xref rid="btad381-B14" ref-type="bibr">Kim <italic toggle="yes">et al.</italic> 2019</xref>, <xref rid="btad381-B26" ref-type="bibr">Wainberg <italic toggle="yes">et al.</italic> 2021</xref>). It seems clear that mapping GI and essentiality networks of cancer-associated genes could reveal biological functions that might be leveraged to inform potential therapeutic strategies.</p>
    <p>The Cancer Dependency Map (DepMap) public data platform (<xref rid="btad381-B17" ref-type="bibr">Meyers <italic toggle="yes">et al.</italic> 2017</xref>, <xref rid="btad381-B10" ref-type="bibr">Ghandi <italic toggle="yes">et al.</italic> 2019</xref>) is the largest resource for mining GIs and essentiality networks of human cancer cell lines. DepMap contains data from multi-omic characterization of cancer cell lines, including whole-genome sequencing, exome sequencing, RNA sequencing (RNA-seq) (<xref rid="btad381-B10" ref-type="bibr">Ghandi <italic toggle="yes">et al.</italic> 2019</xref>), proteomic quantification (<xref rid="btad381-B19" ref-type="bibr">Nusinow <italic toggle="yes">et al.</italic> 2020</xref>), and genome-wide CRISPR-Cas9 KO screens (<xref rid="btad381-B17" ref-type="bibr">Meyers <italic toggle="yes">et al.</italic> 2017</xref>), which are updated bi-annually with additional cancer cell lines (detailed in <ext-link xlink:href="https://depmap.org/portal/announcements/" ext-link-type="uri">https://depmap.org/portal/announcements/</ext-link>). Novel algorithms utilizing DepMap data to predict GIs have emerged (<xref rid="btad381-B8" ref-type="bibr">De Kegel <italic toggle="yes">et al.</italic> 2021</xref>, <xref rid="btad381-B5" ref-type="bibr">Chiu <italic toggle="yes">et al.</italic> 2021</xref>, <xref rid="btad381-B2" ref-type="bibr">Benfatto <italic toggle="yes">et al.</italic> 2021</xref>). However, these tools either lack flexibility, the ability to detect alleviating GIs, or require advanced programming knowledge. Thus, for various reasons, these tools have limited accessibility to the larger research community.</p>
    <p>To facilitate discoveries using GI and essentiality network mapping, we created an R package called Genetic inteRaction and EssenTiality neTwork mApper (GRETTA), which leverages the DepMap data platform. GRETTA provides a simplified approach to query DepMap for user-defined cell line features, including selection by gene, mutation, and cancer types, to predict both lethal and alleviating GIs and essentiality networks. We provide an intuitive method for visualizing results that require only a basic understanding of the R programming language. In addition to the case study, we provide here, we have used GRETTA to reveal functional networks of CIC, a cancer-associated gene (<xref rid="btad381-B25" ref-type="bibr">Takemon <italic toggle="yes">et al.</italic> 2023</xref>). We have thus demonstrated the utility of our tool for discovering genetic interaction and essentiality networks.</p>
  </sec>
  <sec>
    <title>2 Materials and methods</title>
    <sec>
      <title>2.1 Performing <italic toggle="yes">in silico</italic> GI screens</title>
      <p>GRETTA leverages cell line annotations, mutation annotations, copy number quantifications, RNA-seq, proteomic quantifications, and genome-wide CRISPR-Cas9 KO screen data that were made available by the DepMap data platform (<xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref>; <xref rid="btad381-B17" ref-type="bibr">Meyers <italic toggle="yes">et al.</italic> 2017</xref>, <xref rid="btad381-B10" ref-type="bibr">Ghandi <italic toggle="yes">et al.</italic> 2019</xref>, <xref rid="btad381-B19" ref-type="bibr">Nusinow <italic toggle="yes">et al.</italic> 2020</xref>) and predicts candidate GIs in three steps: (i) selecting control and mutant cancer cell lines; (ii) surveying mRNA and/or protein expression changes; and (iii) predicting and visualizing GIs (illustrated in <xref rid="btad381-F1" ref-type="fig">Fig. 1</xref> with a detailed version provided in <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S1A</xref>). Briefly, the first step is driven by a user-defined feature, such as a gene of interest (GOI). By default, when a GOI is provided, all pan-cancer cell lines with wildtype (WT) alleles and neutral copy number of the GOI are assigned to the control group, and lines with loss-of-function alterations in the GOI are assigned to one of the mutant subgroups, including homozygous deletion (HomDel), trans-heterozygous deletion, and heterozygous deletion groups (see <xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref> for details). Cell lines can also be selected by specific mutation, cancer type, or manual curation (<xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref>).</p>
      <fig position="float" id="btad381-F1">
        <label>Figure 1</label>
        <caption>
          <p>An overview of <italic toggle="yes">in silico</italic> GI screening and essentiality mapping using GRETTA. Top panel: A user defines a GOI and/or a cancer type to map GI or essentiality networks. When a cancer type is not defined, GRETTA defaults to a pan-cancer GI screen or essentiality mapping. Left panel: A three-step workflow to predict and visualize candidate GIs of a user-defined GOI in the defined cancer type. After cell lines are grouped into control or mutant groups, the user must select one mutant group based on gene and protein expression phenotypes. The genome-wide KO screen data for this user-selected mutant cell line group are then compared to those of the control group to predict lethal and alleviating GIs. Right panel: Pearson correlation analyses are performed between the KO effect scores of the GOI and each gene that was targeted in DepMap’s genome-wide screen (18 333 genes). The thresholds used to determine co-/antiessential genes are partly determined using inflection points of the ranked positive and negative coefficient curves. A detailed description of the workflow is provided in <xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref>. The DepMap data type processed at each step is illustrated in each subheading and noted in the legend. This figure was partly created with BioRender.com.</p>
        </caption>
        <graphic xlink:href="btad381f1" position="float"/>
      </fig>
      <p>The second step involves extracting DepMap mRNA and protein expression data (if available) and performing differential mRNA and protein expression analyses of the GOI between control cell lines and mutant cell lines (<xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref>). A mutant group with a significant reduction in mRNA or protein expression compared to the control group by Welch’s <italic toggle="yes">t</italic>-test is consistent with a potential reduction of GOI functions, and thus a user may select such a mutant cell line group for downstream analysis.</p>
      <p>Finally, candidate GIs are predicted by conducting differential lethality probability analyses, which identify a gene KO that results in opposing survival outcomes in the mutant cell lines and control cell lines. Mann–Whitney <italic toggle="yes">U</italic> tests are performed by extracting the lethality probabilities of each of the 18 333 genes that were targeted in the DepMap CRISPR-Cas9 KO screen and comparing the control and mutant cancer cell line groups. Optionally, at this step, a list of genes can be provided to perform a small-scale screen. GRETTA also generates an interaction score that is used to visualize candidate GIs and to rank them from most to least likely to be lethal or alleviating (<xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref>).</p>
    </sec>
    <sec>
      <title>2.2 Mapping essentiality networks</title>
      <p>GRETTA adapted a previously published Pearson correlation-based method for mapping essentiality between genes (<xref rid="btad381-B27" ref-type="bibr">Wang <italic toggle="yes">et al.</italic> 2017</xref>, <xref rid="btad381-B20" ref-type="bibr">Pan <italic toggle="yes">et al.</italic> 2018</xref>, <xref rid="btad381-B14" ref-type="bibr">Kim <italic toggle="yes">et al.</italic> 2019</xref>; illustrated in <xref rid="btad381-F1" ref-type="fig">Fig. 1</xref>, <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S1A</xref>; see <xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref> for detailed description). Briefly, the genome-wide CRISPR-Cas9 KO screen data from DepMap is used to calculate pan-cancer essentiality of a gene in the following steps. First, KO effect scores of GOIs (a user-defined input) are extracted from all screened cancer cell lines. Next, Pearson’s correlation coefficients and <italic toggle="yes">P</italic>-values are calculated between the KO effect scores of the GOIs and 18 333 genes screened in the dataset. Next, the inflection point of the ranked positive and negative coefficient score curves is calculated to determine a threshold to identify co-essential (positively correlated) and antiessential (negatively correlated) genes. Finally, a ranked correlation coefficient score is provided as an output and is used to visualize essentiality networks.</p>
    </sec>
  </sec>
  <sec>
    <title>3 Case study: predicting pan-cancer GIs and co-essentiality networks of <italic toggle="yes">ARID1A</italic></title>
    <p><italic toggle="yes">ARID1A</italic> is a member of the mammalian switch/sucrose non-fermentable (SWI/SNF) complex (<xref rid="btad381-B16" ref-type="bibr">Mashtalir <italic toggle="yes">et al.</italic> 2018</xref>) with a known SL GI to its paralog <italic toggle="yes">ARID1B</italic> (<xref rid="btad381-B13" ref-type="bibr">Helming <italic toggle="yes">et al.</italic> 2014</xref>). Rationalizing that this known SL interaction and complex association would serve as positive controls, we applied GRETTA to predict pan-cancer GIs and essentiality networks of <italic toggle="yes">ARID1A</italic>, expecting to replicate known interactors and co-essential genes, respectively. We identified an <italic toggle="yes">ARID1A</italic> WT control group and an <italic toggle="yes">ARID1A</italic> HomDel mutant group, consisting of 906 and 23 cell lines, respectively. The <italic toggle="yes">ARID1A</italic> HomDel mutant group showed significantly reduced <italic toggle="yes">ARID1A</italic> mRNA expression compared to the control group (Welch’s <italic toggle="yes">t</italic>-test <italic toggle="yes">P</italic> &lt;.05; <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S2A</xref> and <xref rid="sup1" ref-type="supplementary-material">B</xref> and <xref rid="sup1" ref-type="supplementary-material">Table S1A</xref> and <xref rid="sup1" ref-type="supplementary-material">B</xref>), consistent with potentially reduced ARID1A function. Using these two groups, we found that <italic toggle="yes">ARID1B</italic> was predicted to be the top lethal genetic interactor of <italic toggle="yes">ARID1A</italic> (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S2C</xref> and <xref rid="sup1" ref-type="supplementary-material">Table S1C</xref>), thus confirming the established SL GI between these two genes. Furthermore, a pan-cancer essentiality analysis of <italic toggle="yes">ARID1A</italic> revealed the expected top five list of co-essential genes that are known mSWI/SNF complex members, namely <italic toggle="yes">ARID1A, SMARCB1</italic>, <italic toggle="yes">SMARCE1</italic>, <italic toggle="yes">SMARCC1</italic>, and <italic toggle="yes">SS18</italic> (<xref rid="btad381-B16" ref-type="bibr">Mashtalir <italic toggle="yes">et al.</italic> 2018</xref>; <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S2D</xref> and <xref rid="sup1" ref-type="supplementary-material">Table S1D</xref>). GRETTA was thus able to recapitulate known GIs and co-essential networks of <italic toggle="yes">ARID1A</italic>.</p>
  </sec>
  <sec>
    <title>4 Discussion</title>
    <p>GRETTA was built to provide an easy-to-use method for mapping GI and essentiality networks. The R package requires only a basic understanding of the R programming language and we provide an easy-to-follow tutorial (<ext-link xlink:href="https://github.com/ytakemon/GRETTA" ext-link-type="uri">https://github.com/ytakemon/GRETTA</ext-link>). Using GRETTA, we replicated known GIs and essentiality networks of ARID1A, thus demonstrating how the tool can be used and ultimately applied to discover GI and essentiality networks of other GOI. We are currently aware of 365 visitors and 135 total unique installations of GRETTA and from this deduce that GRETTA is of interest to the wider research community.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>btad381_Supplementary_Data</label>
      <media xlink:href="btad381_supplementary_data.zip">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ack1">
    <title>Acknowledgements</title>
    <p>We would like to acknowledge the Broad Institute for generating and making their DepMap data platform available for the research community. We would like to thank Drs Anindya Dutta and Yoshiyuki Shibata at the University of Alabama at Birmingham Marnix E. Heersink School of Medicine for testing GRETTA and for the discussions that helped improve its documentation. We would also like to thank Richard Corbett at Canada’s Michael Smith Genome Sciences Centre for the discussion and guidance on containerizing the tool for reproducibility.</p>
  </ack>
  <sec>
    <title>Supplementary data</title>
    <p><xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> is available at <italic toggle="yes">Bioinformatics</italic> online.</p>
  </sec>
  <sec sec-type="COI-statement">
    <title>Conflict of interest</title>
    <p>None declared.</p>
  </sec>
  <sec>
    <title>Funding</title>
    <p>This work was supported by the Canadian Institutes of Health Research (CIHR; FDN-143288) and the Canada Research Chairs to M.A.M.; and the University of British Columbia (UBC) Four-year fellowships (6456, 6569), UBC International Student Award (4884), and UBC President’s Academic Excellence Initiative PhD Award (6817) to Y.T.</p>
  </sec>
  <sec sec-type="data-availability">
    <title>Data availability</title>
    <p>The GRETTA R package, data analyzed in this study (DepMap version 22Q2), and the code used to generate the supplementary figures and tables are publicly available as a tutorial provided on the GRETTA GitHub repository (<ext-link xlink:href="https://github.com/ytakemon/GRETTA" ext-link-type="uri">https://github.com/ytakemon/GRETTA</ext-link>). GRETTA has been archived with a citable DOI on Zenodo (<ext-link xlink:href="https://doi.org/10.5281/zenodo.6940757" ext-link-type="uri">https://doi.org/10.5281/zenodo.6940757</ext-link>) and a Singularity container has been made available on Sylabs (<ext-link xlink:href="https://cloud.sylabs.io/library/ytakemon/gretta/gretta" ext-link-type="uri">https://cloud.sylabs.io/library/ytakemon/gretta/gretta</ext-link>) to ensure reproducibility. GRETTA is shared under the GNU General Public License v3.0.</p>
  </sec>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="btad381-B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Behan</surname><given-names>FM</given-names></string-name>, <string-name><surname>Iorio</surname><given-names>F</given-names></string-name>, <string-name><surname>Picco</surname><given-names>G</given-names></string-name></person-group><etal>et al</etal><article-title>Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens</article-title>. <source>Nature</source><year>2019</year>;<volume>568</volume>:<fpage>511</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">30971826</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Benfatto</surname><given-names>S</given-names></string-name>, <string-name><surname>Serçin</surname><given-names>Ö</given-names></string-name>, <string-name><surname>Dejure</surname><given-names>FR</given-names></string-name></person-group><etal>et al</etal><article-title>Uncovering cancer vulnerabilities by machine learning prediction of synthetic lethality</article-title>. <source>Mol Cancer</source><year>2021</year>;<volume>20</volume>:<fpage>111</fpage>.<pub-id pub-id-type="pmid">34454516</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B4">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bryant</surname><given-names>HE</given-names></string-name>, <string-name><surname>Schultz</surname><given-names>N</given-names></string-name>, <string-name><surname>Thomas</surname><given-names>HD</given-names></string-name></person-group><etal>et al</etal><article-title>Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase</article-title>. <source>Nature</source><year>2005</year>;<volume>434</volume>:<fpage>913</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">15829966</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chiu</surname><given-names>Y-C</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>S</given-names></string-name>, <string-name><surname>Wang</surname><given-names>L-J</given-names></string-name></person-group><etal>et al</etal><article-title>Predicting and characterizing a cancer dependency map of tumors with deep learning</article-title>. <source>Sci Adv</source><year>2021</year>;<volume>7</volume>:eabh1275.</mixed-citation>
    </ref>
    <ref id="btad381-B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>De Kegel</surname><given-names>B</given-names></string-name>, <string-name><surname>Quinn</surname><given-names>N</given-names></string-name>, <string-name><surname>Thompson</surname><given-names>NA</given-names></string-name></person-group><etal>et al</etal><article-title>Comprehensive prediction of robust synthetic lethality between paralog pairs in cancer cell lines</article-title>. <source>Cell Syst</source><year>2021</year>;<volume>12</volume>:<fpage>1144</fpage>–<lpage>59.e6</lpage>. <pub-id pub-id-type="doi">10.1016/j.cels.2021.08.006</pub-id>.<pub-id pub-id-type="pmid">34529928</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B9">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Farmer</surname><given-names>H</given-names></string-name>, <string-name><surname>McCabe</surname><given-names>N</given-names></string-name>, <string-name><surname>Lord</surname><given-names>CJ</given-names></string-name></person-group><etal>et al</etal><article-title>Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</article-title>. <source>Nature</source><year>2005</year>;<volume>434</volume>:<fpage>917</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">15829967</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B21">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Geethakumari</surname><given-names>PR</given-names></string-name>, <string-name><surname>Schiewer</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Knudsen</surname><given-names>KE</given-names></string-name></person-group><etal>et al</etal><article-title>PARP inhibitors in prostate cancer</article-title>. <source>Curr Treat Options Oncol</source><year>2017</year>;<volume>18</volume>:<fpage>37</fpage>.<pub-id pub-id-type="pmid">28540598</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ghandi</surname><given-names>M</given-names></string-name>, <string-name><surname>Huang</surname><given-names>FW</given-names></string-name>, <string-name><surname>Jané-Valbuena</surname><given-names>J</given-names></string-name></person-group><etal>et al</etal><article-title>Next-generation characterization of the cancer cell line encyclopedia</article-title>. <source>Nature</source><year>2019</year>;<volume>569</volume>:<fpage>503</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">31068700</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hart</surname><given-names>T</given-names></string-name>, <string-name><surname>Chandrashekhar</surname><given-names>M</given-names></string-name>, <string-name><surname>Aregger</surname><given-names>M</given-names></string-name></person-group><etal>et al</etal><article-title>High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities</article-title>. <source>Cell</source><year>2015</year>;<volume>163</volume>:<fpage>1515</fpage>–<lpage>26</lpage>.<pub-id pub-id-type="pmid">26627737</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Helming</surname><given-names>KC</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>BG</given-names></string-name></person-group><etal>et al</etal><article-title>ARID1B is a specific vulnerability in ARID1A-mutant cancers</article-title>. <source>Nat Med</source><year>2014</year>;<volume>20</volume>:<fpage>251</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">24562383</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B14">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname><given-names>E</given-names></string-name>, <string-name><surname>Dede</surname><given-names>M</given-names></string-name>, <string-name><surname>Lenoir</surname><given-names>WF</given-names></string-name></person-group><etal>et al</etal><article-title>A network of human functional gene interactions from knockout fitness screens in cancer cells</article-title>. <source>Life Sci Alliance</source><year>2019</year>;<volume>2</volume>:<fpage>e201800278</fpage>.<pub-id pub-id-type="pmid">30979825</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B15">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mani</surname><given-names>R</given-names></string-name>, <string-name><surname>St Onge</surname><given-names>RP</given-names></string-name>, <string-name><surname>Hartman</surname><given-names>JL</given-names></string-name></person-group><etal>et al</etal><article-title>Defining genetic interaction</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2008</year>;<volume>105</volume>:<fpage>3461</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">18305163</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mashtalir</surname><given-names>N</given-names></string-name>, <string-name><surname>D'Avino</surname><given-names>AR</given-names></string-name>, <string-name><surname>Michel</surname><given-names>BC</given-names></string-name></person-group><etal>et al</etal><article-title>Modular organization and assembly of SWI/SNF family chromatin remodeling complexes</article-title>. <source>Cell</source><year>2018</year>;<volume>175</volume>:<fpage>1272</fpage>–<lpage>88.e20</lpage>.<pub-id pub-id-type="pmid">30343899</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B17">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Meyers</surname><given-names>RM</given-names></string-name>, <string-name><surname>Bryan</surname><given-names>JG</given-names></string-name>, <string-name><surname>McFarland</surname><given-names>JM</given-names></string-name></person-group><etal>et al</etal><article-title>Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells</article-title>. <source>Nat Genet</source><year>2017</year>;<volume>49</volume>:<fpage>1779</fpage>–<lpage>84</lpage>.<pub-id pub-id-type="pmid">29083409</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B18">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mirza</surname><given-names>MR</given-names></string-name>, <string-name><surname>Pignata</surname><given-names>S</given-names></string-name>, <string-name><surname>Ledermann</surname><given-names>JA</given-names></string-name></person-group><etal>et al</etal><article-title>Latest clinical evidence and further development of PARP inhibitors in ovarian cancer</article-title>. <source>Ann Oncol</source><year>2018</year>;<volume>29</volume>:<fpage>1366</fpage>–<lpage>76</lpage>.<pub-id pub-id-type="pmid">29750420</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B19">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nusinow</surname><given-names>DP</given-names></string-name>, <string-name><surname>Szpyt</surname><given-names>J</given-names></string-name>, <string-name><surname>Ghandi</surname><given-names>M</given-names></string-name></person-group><etal>et al</etal><article-title>Quantitative proteomics of the cancer cell line encyclopedia</article-title>. <source>Cell</source><year>2020</year>;<volume>180</volume>:<fpage>387</fpage>–<lpage>402.e16</lpage>.<pub-id pub-id-type="pmid">31978347</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B20">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pan</surname><given-names>J</given-names></string-name>, <string-name><surname>Meyers</surname><given-names>RM</given-names></string-name>, <string-name><surname>Michel</surname><given-names>BC</given-names></string-name></person-group><etal>et al</etal><article-title>Interrogation of mammalian protein complex structure, function, and membership using Genome-Scale fitness screens</article-title>. <source>Cell Syst</source><year>2018</year>;<volume>6</volume>:<fpage>555</fpage>–<lpage>68.e7</lpage>.<pub-id pub-id-type="pmid">29778836</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B22">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Robson</surname><given-names>M</given-names></string-name>, <string-name><surname>Goessl</surname><given-names>C</given-names></string-name>, <string-name><surname>Domchek</surname><given-names>S</given-names></string-name></person-group><etal>et al</etal><article-title>Olaparib for metastatic germline BRCA-mutated breast cancer</article-title>. <source>N Engl J Med</source><year>2017</year>;<volume>377</volume>:<fpage>1792</fpage>–<lpage>3</lpage>.</mixed-citation>
    </ref>
    <ref id="btad381-B23">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Robson</surname><given-names>ME</given-names></string-name>, <string-name><surname>Tung</surname><given-names>N</given-names></string-name>, <string-name><surname>Conte</surname><given-names>P</given-names></string-name></person-group><etal>et al</etal><article-title>OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer</article-title>. <source>Ann Oncol</source><year>2019</year>;<volume>30</volume>:<fpage>558</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="pmid">30689707</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B24">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shalem</surname><given-names>O</given-names></string-name>, <string-name><surname>Sanjana</surname><given-names>NE</given-names></string-name>, <string-name><surname>Hartenian</surname><given-names>E</given-names></string-name></person-group><etal>et al</etal><article-title>Genome-scale CRISPR-Cas9 knockout screening in human cells</article-title>. <source>Science</source><year>2014</year>;<volume>343</volume>:<fpage>84</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">24336571</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B25">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Takemon</surname><given-names>Y</given-names></string-name>, <string-name><surname>LeBlanc</surname><given-names>VG</given-names></string-name>, <string-name><surname>Song</surname><given-names>J</given-names></string-name></person-group><etal>et al</etal><article-title>Multi-omic analysis of CIC’s functional networks reveals novel interaction partners and a potential role in mitotic fidelity</article-title>. <source>Cancers</source><year>2023</year>;<volume>15</volume>:<fpage>2805</fpage>.</mixed-citation>
    </ref>
    <ref id="btad381-B26">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wainberg</surname><given-names>M</given-names></string-name>, <string-name><surname>Kamber</surname><given-names>RA</given-names></string-name>, <string-name><surname>Balsubramani</surname><given-names>A</given-names></string-name></person-group><etal>et al</etal><article-title>A genome-wide atlas of co-essential modules assigns function to uncharacterized genes</article-title>. <source>Nat Genet</source><year>2021</year>;<volume>53</volume>:<fpage>638</fpage>–<lpage>49</lpage>.<pub-id pub-id-type="pmid">33859415</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B27">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>T</given-names></string-name>, <string-name><surname>Yu</surname><given-names>H</given-names></string-name>, <string-name><surname>Hughes</surname><given-names>NW</given-names></string-name></person-group><etal>et al</etal><article-title>Gene essentiality profiling reveals gene networks and synthetic lethal interactions with oncogenic ras</article-title>. <source>Cell</source><year>2017</year>;<volume>168</volume>:<fpage>890</fpage>–<lpage>903.e15</lpage>.<pub-id pub-id-type="pmid">28162770</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Bioinformatics</journal-id>
    <journal-id journal-id-type="iso-abbrev">Bioinformatics</journal-id>
    <journal-id journal-id-type="publisher-id">bioinformatics</journal-id>
    <journal-title-group>
      <journal-title>Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1367-4803</issn>
    <issn pub-type="epub">1367-4811</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10284671</article-id>
    <article-id pub-id-type="pmid">37326978</article-id>
    <article-id pub-id-type="doi">10.1093/bioinformatics/btad381</article-id>
    <article-id pub-id-type="publisher-id">btad381</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Applications Note</subject>
        <subj-group subj-group-type="category-toc-heading">
          <subject>Systems Biology</subject>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI01060</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>GRETTA: an R package for mapping <italic toggle="yes">in silico</italic> genetic interaction and essentiality networks</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3538-4409</contrib-id>
        <name>
          <surname>Takemon</surname>
          <given-names>Yuka</given-names>
        </name>
        <aff><institution>Genome Science and Technology Graduate Program, University of British Columbia</institution>, Vancouver, BC V5Z 4S6, <country country="CA">Canada</country></aff>
        <aff><institution>Michael Smith Laboratories, University of British Columbia</institution>, Vancouver, BC V6T 1Z4, <country country="CA">Canada</country></aff>
        <aff><institution>Canada’s Michael Smith Genome Sciences Centre, BC Cancer Research Institute</institution>, Vancouver, BC V5Z 4S6, <country country="CA">Canada</country></aff>
        <!--ytakemon@bcgsc.ca-->
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7146-7175</contrib-id>
        <name>
          <surname>Marra</surname>
          <given-names>Marco A</given-names>
        </name>
        <aff><institution>Michael Smith Laboratories, University of British Columbia</institution>, Vancouver, BC V6T 1Z4, <country country="CA">Canada</country></aff>
        <aff><institution>Canada’s Michael Smith Genome Sciences Centre, BC Cancer Research Institute</institution>, Vancouver, BC V5Z 4S6, <country country="CA">Canada</country></aff>
        <aff><institution>Department of Medical Genetics, University of British Columbia</institution>, Vancouver, BC V6H 3N1, <country country="CA">Canada</country></aff>
        <!--mmarra@bcgsc.ca-->
        <xref rid="btad381-cor1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Kelso</surname>
          <given-names>Janet</given-names>
        </name>
        <role>Associate Editor</role>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="btad381-cor1">Corresponding author. Michael Smith Laboratories, University of British Columbia, 301-2185 East Mall, Vancouver, BC V6T 1Z4, Canada. E-mail: <email>mmarra@bcgsc.ca</email> (M.A.M.)</corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <month>6</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2023-06-16">
      <day>16</day>
      <month>6</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>16</day>
      <month>6</month>
      <year>2023</year>
    </pub-date>
    <volume>39</volume>
    <issue>6</issue>
    <elocation-id>btad381</elocation-id>
    <history>
      <date date-type="received">
        <day>21</day>
        <month>9</month>
        <year>2022</year>
      </date>
      <date date-type="rev-recd">
        <day>02</day>
        <month>6</month>
        <year>2023</year>
      </date>
      <date date-type="editorial-decision">
        <day>07</day>
        <month>6</month>
        <year>2023</year>
      </date>
      <date date-type="corrected-typeset">
        <day>21</day>
        <month>6</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2023. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2023</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="btad381.pdf"/>
    <abstract>
      <title>Abstract</title>
      <sec id="s1">
        <title>Summary</title>
        <p>Mapping genetic interactions and essentiality networks in human cell lines has been used to identify vulnerabilities of cells carrying specific genetic alterations and to associate novel functions to genes, respectively. <italic toggle="yes">In vitro</italic> and <italic toggle="yes">in vivo</italic> genetic screens to decipher these networks are resource-intensive, limiting the throughput of samples that can be analyzed. In this application note, we provide an R package we call Genetic inteRaction and EssenTiality neTwork mApper (GRETTA). GRETTA is an accessible tool for <italic toggle="yes">in silico</italic> genetic interaction screens and essentiality network analyses using publicly available data, requiring only basic R programming knowledge.</p>
      </sec>
      <sec id="s2">
        <title>Availability and implementation</title>
        <p>The R package, GRETTA, is licensed under GNU General Public License v3.0 and freely available at <ext-link xlink:href="https://github.com/ytakemon/GRETTA" ext-link-type="uri">https://github.com/ytakemon/GRETTA</ext-link> and <ext-link xlink:href="https://doi.org/10.5281/zenodo.6940757" ext-link-type="uri">https://doi.org/10.5281/zenodo.6940757</ext-link>, with documentation and tutorial. A Singularity container is also available at <ext-link xlink:href="https://cloud.sylabs.io/library/ytakemon/gretta/gretta" ext-link-type="uri">https://cloud.sylabs.io/library/ytakemon/gretta/gretta</ext-link>.</p>
      </sec>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Canadian Institutes of Health Research</institution>
            <institution-id institution-id-type="DOI">10.13039/501100000024</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>FDN-143288</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="4"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec>
    <title>1 Introduction</title>
    <p>Genetic perturbation screens, such as CRISPR-Cas9 knockout (KO) screens, have been used to uncover lethal and alleviating genetic interactions (GIs; <xref rid="btad381-B24" ref-type="bibr">Shalem <italic toggle="yes">et al.</italic> 2014</xref>, <xref rid="btad381-B11" ref-type="bibr">Hart <italic toggle="yes">et al.</italic> 2015</xref>, <xref rid="btad381-B27" ref-type="bibr">Wang <italic toggle="yes">et al.</italic> 2017</xref>, <xref rid="btad381-B1" ref-type="bibr">Behan <italic toggle="yes">et al.</italic> 2019</xref>) and essentiality networks to decipher a gene’s functional membership (<xref rid="btad381-B20" ref-type="bibr">Pan <italic toggle="yes">et al.</italic> 2018</xref>, <xref rid="btad381-B26" ref-type="bibr">Wainberg <italic toggle="yes">et al.</italic> 2021</xref>). Two genes are said to share a lethal, or synthetic lethal (SL), GI when the perturbation of both genes together in the same cell impedes cell viability, but perturbation of either gene individually has no impact on viability (<xref rid="btad381-B15" ref-type="bibr">Mani <italic toggle="yes">et al.</italic> 2008</xref>). Conversely, an alleviating GI occurs when the perturbation of two genes leads to a fitness advantage over cells with either gene perturbed individually (<xref rid="btad381-B15" ref-type="bibr">Mani <italic toggle="yes">et al.</italic> 2008</xref>). Lethal GIs of genes mutated in cancers have revealed tumor-specific vulnerabilities that can be therapeutically exploited. Most notable are the lethal GIs between <italic toggle="yes">BRCA1/2</italic> and <italic toggle="yes">PARP1</italic> (<xref rid="btad381-B4" ref-type="bibr">Bryant <italic toggle="yes">et al.</italic> 2005</xref>, <xref rid="btad381-B9" ref-type="bibr">Farmer <italic toggle="yes">et al.</italic> 2005</xref>), which led to the use of PARP inhibitors in BRCA1/2-deficient breast (<xref rid="btad381-B22" ref-type="bibr">Robson <italic toggle="yes">et al.</italic> 2017</xref>, <xref rid="btad381-B23" ref-type="bibr">2019</xref>), ovarian (<xref rid="btad381-B18" ref-type="bibr">Mirza <italic toggle="yes">et al.</italic> 2018</xref>), and prostate cancers (<xref rid="btad381-B21" ref-type="bibr">Ramakrishnan Geethakumari <italic toggle="yes">et al.</italic> 2017</xref>). Essentiality network maps have been utilized to assign novel functions to genes (<xref rid="btad381-B27" ref-type="bibr">Wang <italic toggle="yes">et al.</italic> 2017</xref>, <xref rid="btad381-B14" ref-type="bibr">Kim <italic toggle="yes">et al.</italic> 2019</xref>, <xref rid="btad381-B26" ref-type="bibr">Wainberg <italic toggle="yes">et al.</italic> 2021</xref>, <xref rid="btad381-B20" ref-type="bibr">Pan <italic toggle="yes">et al.</italic> 2018</xref>). Two genes share co-essentiality when perturbation of either gene leads to similar fitness effects in cells. This is interpreted to indicate that the genes may have similar or synergistic functions (<xref rid="btad381-B14" ref-type="bibr">Kim <italic toggle="yes">et al.</italic> 2019</xref>, <xref rid="btad381-B26" ref-type="bibr">Wainberg <italic toggle="yes">et al.</italic> 2021</xref>). In contrast, two genes are antiessential when perturbations in either of them lead to opposite cellular fitness effects. This is interpreted to indicate genes with inhibitory or antagonistic relationships (<xref rid="btad381-B14" ref-type="bibr">Kim <italic toggle="yes">et al.</italic> 2019</xref>, <xref rid="btad381-B26" ref-type="bibr">Wainberg <italic toggle="yes">et al.</italic> 2021</xref>). It seems clear that mapping GI and essentiality networks of cancer-associated genes could reveal biological functions that might be leveraged to inform potential therapeutic strategies.</p>
    <p>The Cancer Dependency Map (DepMap) public data platform (<xref rid="btad381-B17" ref-type="bibr">Meyers <italic toggle="yes">et al.</italic> 2017</xref>, <xref rid="btad381-B10" ref-type="bibr">Ghandi <italic toggle="yes">et al.</italic> 2019</xref>) is the largest resource for mining GIs and essentiality networks of human cancer cell lines. DepMap contains data from multi-omic characterization of cancer cell lines, including whole-genome sequencing, exome sequencing, RNA sequencing (RNA-seq) (<xref rid="btad381-B10" ref-type="bibr">Ghandi <italic toggle="yes">et al.</italic> 2019</xref>), proteomic quantification (<xref rid="btad381-B19" ref-type="bibr">Nusinow <italic toggle="yes">et al.</italic> 2020</xref>), and genome-wide CRISPR-Cas9 KO screens (<xref rid="btad381-B17" ref-type="bibr">Meyers <italic toggle="yes">et al.</italic> 2017</xref>), which are updated bi-annually with additional cancer cell lines (detailed in <ext-link xlink:href="https://depmap.org/portal/announcements/" ext-link-type="uri">https://depmap.org/portal/announcements/</ext-link>). Novel algorithms utilizing DepMap data to predict GIs have emerged (<xref rid="btad381-B8" ref-type="bibr">De Kegel <italic toggle="yes">et al.</italic> 2021</xref>, <xref rid="btad381-B5" ref-type="bibr">Chiu <italic toggle="yes">et al.</italic> 2021</xref>, <xref rid="btad381-B2" ref-type="bibr">Benfatto <italic toggle="yes">et al.</italic> 2021</xref>). However, these tools either lack flexibility, the ability to detect alleviating GIs, or require advanced programming knowledge. Thus, for various reasons, these tools have limited accessibility to the larger research community.</p>
    <p>To facilitate discoveries using GI and essentiality network mapping, we created an R package called Genetic inteRaction and EssenTiality neTwork mApper (GRETTA), which leverages the DepMap data platform. GRETTA provides a simplified approach to query DepMap for user-defined cell line features, including selection by gene, mutation, and cancer types, to predict both lethal and alleviating GIs and essentiality networks. We provide an intuitive method for visualizing results that require only a basic understanding of the R programming language. In addition to the case study, we provide here, we have used GRETTA to reveal functional networks of CIC, a cancer-associated gene (<xref rid="btad381-B25" ref-type="bibr">Takemon <italic toggle="yes">et al.</italic> 2023</xref>). We have thus demonstrated the utility of our tool for discovering genetic interaction and essentiality networks.</p>
  </sec>
  <sec>
    <title>2 Materials and methods</title>
    <sec>
      <title>2.1 Performing <italic toggle="yes">in silico</italic> GI screens</title>
      <p>GRETTA leverages cell line annotations, mutation annotations, copy number quantifications, RNA-seq, proteomic quantifications, and genome-wide CRISPR-Cas9 KO screen data that were made available by the DepMap data platform (<xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref>; <xref rid="btad381-B17" ref-type="bibr">Meyers <italic toggle="yes">et al.</italic> 2017</xref>, <xref rid="btad381-B10" ref-type="bibr">Ghandi <italic toggle="yes">et al.</italic> 2019</xref>, <xref rid="btad381-B19" ref-type="bibr">Nusinow <italic toggle="yes">et al.</italic> 2020</xref>) and predicts candidate GIs in three steps: (i) selecting control and mutant cancer cell lines; (ii) surveying mRNA and/or protein expression changes; and (iii) predicting and visualizing GIs (illustrated in <xref rid="btad381-F1" ref-type="fig">Fig. 1</xref> with a detailed version provided in <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S1A</xref>). Briefly, the first step is driven by a user-defined feature, such as a gene of interest (GOI). By default, when a GOI is provided, all pan-cancer cell lines with wildtype (WT) alleles and neutral copy number of the GOI are assigned to the control group, and lines with loss-of-function alterations in the GOI are assigned to one of the mutant subgroups, including homozygous deletion (HomDel), trans-heterozygous deletion, and heterozygous deletion groups (see <xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref> for details). Cell lines can also be selected by specific mutation, cancer type, or manual curation (<xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref>).</p>
      <fig position="float" id="btad381-F1">
        <label>Figure 1</label>
        <caption>
          <p>An overview of <italic toggle="yes">in silico</italic> GI screening and essentiality mapping using GRETTA. Top panel: A user defines a GOI and/or a cancer type to map GI or essentiality networks. When a cancer type is not defined, GRETTA defaults to a pan-cancer GI screen or essentiality mapping. Left panel: A three-step workflow to predict and visualize candidate GIs of a user-defined GOI in the defined cancer type. After cell lines are grouped into control or mutant groups, the user must select one mutant group based on gene and protein expression phenotypes. The genome-wide KO screen data for this user-selected mutant cell line group are then compared to those of the control group to predict lethal and alleviating GIs. Right panel: Pearson correlation analyses are performed between the KO effect scores of the GOI and each gene that was targeted in DepMap’s genome-wide screen (18 333 genes). The thresholds used to determine co-/antiessential genes are partly determined using inflection points of the ranked positive and negative coefficient curves. A detailed description of the workflow is provided in <xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref>. The DepMap data type processed at each step is illustrated in each subheading and noted in the legend. This figure was partly created with BioRender.com.</p>
        </caption>
        <graphic xlink:href="btad381f1" position="float"/>
      </fig>
      <p>The second step involves extracting DepMap mRNA and protein expression data (if available) and performing differential mRNA and protein expression analyses of the GOI between control cell lines and mutant cell lines (<xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref>). A mutant group with a significant reduction in mRNA or protein expression compared to the control group by Welch’s <italic toggle="yes">t</italic>-test is consistent with a potential reduction of GOI functions, and thus a user may select such a mutant cell line group for downstream analysis.</p>
      <p>Finally, candidate GIs are predicted by conducting differential lethality probability analyses, which identify a gene KO that results in opposing survival outcomes in the mutant cell lines and control cell lines. Mann–Whitney <italic toggle="yes">U</italic> tests are performed by extracting the lethality probabilities of each of the 18 333 genes that were targeted in the DepMap CRISPR-Cas9 KO screen and comparing the control and mutant cancer cell line groups. Optionally, at this step, a list of genes can be provided to perform a small-scale screen. GRETTA also generates an interaction score that is used to visualize candidate GIs and to rank them from most to least likely to be lethal or alleviating (<xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref>).</p>
    </sec>
    <sec>
      <title>2.2 Mapping essentiality networks</title>
      <p>GRETTA adapted a previously published Pearson correlation-based method for mapping essentiality between genes (<xref rid="btad381-B27" ref-type="bibr">Wang <italic toggle="yes">et al.</italic> 2017</xref>, <xref rid="btad381-B20" ref-type="bibr">Pan <italic toggle="yes">et al.</italic> 2018</xref>, <xref rid="btad381-B14" ref-type="bibr">Kim <italic toggle="yes">et al.</italic> 2019</xref>; illustrated in <xref rid="btad381-F1" ref-type="fig">Fig. 1</xref>, <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S1A</xref>; see <xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref> for detailed description). Briefly, the genome-wide CRISPR-Cas9 KO screen data from DepMap is used to calculate pan-cancer essentiality of a gene in the following steps. First, KO effect scores of GOIs (a user-defined input) are extracted from all screened cancer cell lines. Next, Pearson’s correlation coefficients and <italic toggle="yes">P</italic>-values are calculated between the KO effect scores of the GOIs and 18 333 genes screened in the dataset. Next, the inflection point of the ranked positive and negative coefficient score curves is calculated to determine a threshold to identify co-essential (positively correlated) and antiessential (negatively correlated) genes. Finally, a ranked correlation coefficient score is provided as an output and is used to visualize essentiality networks.</p>
    </sec>
  </sec>
  <sec>
    <title>3 Case study: predicting pan-cancer GIs and co-essentiality networks of <italic toggle="yes">ARID1A</italic></title>
    <p><italic toggle="yes">ARID1A</italic> is a member of the mammalian switch/sucrose non-fermentable (SWI/SNF) complex (<xref rid="btad381-B16" ref-type="bibr">Mashtalir <italic toggle="yes">et al.</italic> 2018</xref>) with a known SL GI to its paralog <italic toggle="yes">ARID1B</italic> (<xref rid="btad381-B13" ref-type="bibr">Helming <italic toggle="yes">et al.</italic> 2014</xref>). Rationalizing that this known SL interaction and complex association would serve as positive controls, we applied GRETTA to predict pan-cancer GIs and essentiality networks of <italic toggle="yes">ARID1A</italic>, expecting to replicate known interactors and co-essential genes, respectively. We identified an <italic toggle="yes">ARID1A</italic> WT control group and an <italic toggle="yes">ARID1A</italic> HomDel mutant group, consisting of 906 and 23 cell lines, respectively. The <italic toggle="yes">ARID1A</italic> HomDel mutant group showed significantly reduced <italic toggle="yes">ARID1A</italic> mRNA expression compared to the control group (Welch’s <italic toggle="yes">t</italic>-test <italic toggle="yes">P</italic> &lt;.05; <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S2A</xref> and <xref rid="sup1" ref-type="supplementary-material">B</xref> and <xref rid="sup1" ref-type="supplementary-material">Table S1A</xref> and <xref rid="sup1" ref-type="supplementary-material">B</xref>), consistent with potentially reduced ARID1A function. Using these two groups, we found that <italic toggle="yes">ARID1B</italic> was predicted to be the top lethal genetic interactor of <italic toggle="yes">ARID1A</italic> (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S2C</xref> and <xref rid="sup1" ref-type="supplementary-material">Table S1C</xref>), thus confirming the established SL GI between these two genes. Furthermore, a pan-cancer essentiality analysis of <italic toggle="yes">ARID1A</italic> revealed the expected top five list of co-essential genes that are known mSWI/SNF complex members, namely <italic toggle="yes">ARID1A, SMARCB1</italic>, <italic toggle="yes">SMARCE1</italic>, <italic toggle="yes">SMARCC1</italic>, and <italic toggle="yes">SS18</italic> (<xref rid="btad381-B16" ref-type="bibr">Mashtalir <italic toggle="yes">et al.</italic> 2018</xref>; <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S2D</xref> and <xref rid="sup1" ref-type="supplementary-material">Table S1D</xref>). GRETTA was thus able to recapitulate known GIs and co-essential networks of <italic toggle="yes">ARID1A</italic>.</p>
  </sec>
  <sec>
    <title>4 Discussion</title>
    <p>GRETTA was built to provide an easy-to-use method for mapping GI and essentiality networks. The R package requires only a basic understanding of the R programming language and we provide an easy-to-follow tutorial (<ext-link xlink:href="https://github.com/ytakemon/GRETTA" ext-link-type="uri">https://github.com/ytakemon/GRETTA</ext-link>). Using GRETTA, we replicated known GIs and essentiality networks of ARID1A, thus demonstrating how the tool can be used and ultimately applied to discover GI and essentiality networks of other GOI. We are currently aware of 365 visitors and 135 total unique installations of GRETTA and from this deduce that GRETTA is of interest to the wider research community.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>btad381_Supplementary_Data</label>
      <media xlink:href="btad381_supplementary_data.zip">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ack1">
    <title>Acknowledgements</title>
    <p>We would like to acknowledge the Broad Institute for generating and making their DepMap data platform available for the research community. We would like to thank Drs Anindya Dutta and Yoshiyuki Shibata at the University of Alabama at Birmingham Marnix E. Heersink School of Medicine for testing GRETTA and for the discussions that helped improve its documentation. We would also like to thank Richard Corbett at Canada’s Michael Smith Genome Sciences Centre for the discussion and guidance on containerizing the tool for reproducibility.</p>
  </ack>
  <sec>
    <title>Supplementary data</title>
    <p><xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> is available at <italic toggle="yes">Bioinformatics</italic> online.</p>
  </sec>
  <sec sec-type="COI-statement">
    <title>Conflict of interest</title>
    <p>None declared.</p>
  </sec>
  <sec>
    <title>Funding</title>
    <p>This work was supported by the Canadian Institutes of Health Research (CIHR; FDN-143288) and the Canada Research Chairs to M.A.M.; and the University of British Columbia (UBC) Four-year fellowships (6456, 6569), UBC International Student Award (4884), and UBC President’s Academic Excellence Initiative PhD Award (6817) to Y.T.</p>
  </sec>
  <sec sec-type="data-availability">
    <title>Data availability</title>
    <p>The GRETTA R package, data analyzed in this study (DepMap version 22Q2), and the code used to generate the supplementary figures and tables are publicly available as a tutorial provided on the GRETTA GitHub repository (<ext-link xlink:href="https://github.com/ytakemon/GRETTA" ext-link-type="uri">https://github.com/ytakemon/GRETTA</ext-link>). GRETTA has been archived with a citable DOI on Zenodo (<ext-link xlink:href="https://doi.org/10.5281/zenodo.6940757" ext-link-type="uri">https://doi.org/10.5281/zenodo.6940757</ext-link>) and a Singularity container has been made available on Sylabs (<ext-link xlink:href="https://cloud.sylabs.io/library/ytakemon/gretta/gretta" ext-link-type="uri">https://cloud.sylabs.io/library/ytakemon/gretta/gretta</ext-link>) to ensure reproducibility. GRETTA is shared under the GNU General Public License v3.0.</p>
  </sec>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="btad381-B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Behan</surname><given-names>FM</given-names></string-name>, <string-name><surname>Iorio</surname><given-names>F</given-names></string-name>, <string-name><surname>Picco</surname><given-names>G</given-names></string-name></person-group><etal>et al</etal><article-title>Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens</article-title>. <source>Nature</source><year>2019</year>;<volume>568</volume>:<fpage>511</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">30971826</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Benfatto</surname><given-names>S</given-names></string-name>, <string-name><surname>Serçin</surname><given-names>Ö</given-names></string-name>, <string-name><surname>Dejure</surname><given-names>FR</given-names></string-name></person-group><etal>et al</etal><article-title>Uncovering cancer vulnerabilities by machine learning prediction of synthetic lethality</article-title>. <source>Mol Cancer</source><year>2021</year>;<volume>20</volume>:<fpage>111</fpage>.<pub-id pub-id-type="pmid">34454516</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B4">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bryant</surname><given-names>HE</given-names></string-name>, <string-name><surname>Schultz</surname><given-names>N</given-names></string-name>, <string-name><surname>Thomas</surname><given-names>HD</given-names></string-name></person-group><etal>et al</etal><article-title>Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase</article-title>. <source>Nature</source><year>2005</year>;<volume>434</volume>:<fpage>913</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">15829966</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chiu</surname><given-names>Y-C</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>S</given-names></string-name>, <string-name><surname>Wang</surname><given-names>L-J</given-names></string-name></person-group><etal>et al</etal><article-title>Predicting and characterizing a cancer dependency map of tumors with deep learning</article-title>. <source>Sci Adv</source><year>2021</year>;<volume>7</volume>:eabh1275.</mixed-citation>
    </ref>
    <ref id="btad381-B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>De Kegel</surname><given-names>B</given-names></string-name>, <string-name><surname>Quinn</surname><given-names>N</given-names></string-name>, <string-name><surname>Thompson</surname><given-names>NA</given-names></string-name></person-group><etal>et al</etal><article-title>Comprehensive prediction of robust synthetic lethality between paralog pairs in cancer cell lines</article-title>. <source>Cell Syst</source><year>2021</year>;<volume>12</volume>:<fpage>1144</fpage>–<lpage>59.e6</lpage>. <pub-id pub-id-type="doi">10.1016/j.cels.2021.08.006</pub-id>.<pub-id pub-id-type="pmid">34529928</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B9">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Farmer</surname><given-names>H</given-names></string-name>, <string-name><surname>McCabe</surname><given-names>N</given-names></string-name>, <string-name><surname>Lord</surname><given-names>CJ</given-names></string-name></person-group><etal>et al</etal><article-title>Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</article-title>. <source>Nature</source><year>2005</year>;<volume>434</volume>:<fpage>917</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">15829967</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B21">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Geethakumari</surname><given-names>PR</given-names></string-name>, <string-name><surname>Schiewer</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Knudsen</surname><given-names>KE</given-names></string-name></person-group><etal>et al</etal><article-title>PARP inhibitors in prostate cancer</article-title>. <source>Curr Treat Options Oncol</source><year>2017</year>;<volume>18</volume>:<fpage>37</fpage>.<pub-id pub-id-type="pmid">28540598</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ghandi</surname><given-names>M</given-names></string-name>, <string-name><surname>Huang</surname><given-names>FW</given-names></string-name>, <string-name><surname>Jané-Valbuena</surname><given-names>J</given-names></string-name></person-group><etal>et al</etal><article-title>Next-generation characterization of the cancer cell line encyclopedia</article-title>. <source>Nature</source><year>2019</year>;<volume>569</volume>:<fpage>503</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">31068700</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hart</surname><given-names>T</given-names></string-name>, <string-name><surname>Chandrashekhar</surname><given-names>M</given-names></string-name>, <string-name><surname>Aregger</surname><given-names>M</given-names></string-name></person-group><etal>et al</etal><article-title>High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities</article-title>. <source>Cell</source><year>2015</year>;<volume>163</volume>:<fpage>1515</fpage>–<lpage>26</lpage>.<pub-id pub-id-type="pmid">26627737</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Helming</surname><given-names>KC</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>BG</given-names></string-name></person-group><etal>et al</etal><article-title>ARID1B is a specific vulnerability in ARID1A-mutant cancers</article-title>. <source>Nat Med</source><year>2014</year>;<volume>20</volume>:<fpage>251</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">24562383</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B14">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname><given-names>E</given-names></string-name>, <string-name><surname>Dede</surname><given-names>M</given-names></string-name>, <string-name><surname>Lenoir</surname><given-names>WF</given-names></string-name></person-group><etal>et al</etal><article-title>A network of human functional gene interactions from knockout fitness screens in cancer cells</article-title>. <source>Life Sci Alliance</source><year>2019</year>;<volume>2</volume>:<fpage>e201800278</fpage>.<pub-id pub-id-type="pmid">30979825</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B15">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mani</surname><given-names>R</given-names></string-name>, <string-name><surname>St Onge</surname><given-names>RP</given-names></string-name>, <string-name><surname>Hartman</surname><given-names>JL</given-names></string-name></person-group><etal>et al</etal><article-title>Defining genetic interaction</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2008</year>;<volume>105</volume>:<fpage>3461</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">18305163</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mashtalir</surname><given-names>N</given-names></string-name>, <string-name><surname>D'Avino</surname><given-names>AR</given-names></string-name>, <string-name><surname>Michel</surname><given-names>BC</given-names></string-name></person-group><etal>et al</etal><article-title>Modular organization and assembly of SWI/SNF family chromatin remodeling complexes</article-title>. <source>Cell</source><year>2018</year>;<volume>175</volume>:<fpage>1272</fpage>–<lpage>88.e20</lpage>.<pub-id pub-id-type="pmid">30343899</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B17">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Meyers</surname><given-names>RM</given-names></string-name>, <string-name><surname>Bryan</surname><given-names>JG</given-names></string-name>, <string-name><surname>McFarland</surname><given-names>JM</given-names></string-name></person-group><etal>et al</etal><article-title>Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells</article-title>. <source>Nat Genet</source><year>2017</year>;<volume>49</volume>:<fpage>1779</fpage>–<lpage>84</lpage>.<pub-id pub-id-type="pmid">29083409</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B18">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mirza</surname><given-names>MR</given-names></string-name>, <string-name><surname>Pignata</surname><given-names>S</given-names></string-name>, <string-name><surname>Ledermann</surname><given-names>JA</given-names></string-name></person-group><etal>et al</etal><article-title>Latest clinical evidence and further development of PARP inhibitors in ovarian cancer</article-title>. <source>Ann Oncol</source><year>2018</year>;<volume>29</volume>:<fpage>1366</fpage>–<lpage>76</lpage>.<pub-id pub-id-type="pmid">29750420</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B19">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nusinow</surname><given-names>DP</given-names></string-name>, <string-name><surname>Szpyt</surname><given-names>J</given-names></string-name>, <string-name><surname>Ghandi</surname><given-names>M</given-names></string-name></person-group><etal>et al</etal><article-title>Quantitative proteomics of the cancer cell line encyclopedia</article-title>. <source>Cell</source><year>2020</year>;<volume>180</volume>:<fpage>387</fpage>–<lpage>402.e16</lpage>.<pub-id pub-id-type="pmid">31978347</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B20">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pan</surname><given-names>J</given-names></string-name>, <string-name><surname>Meyers</surname><given-names>RM</given-names></string-name>, <string-name><surname>Michel</surname><given-names>BC</given-names></string-name></person-group><etal>et al</etal><article-title>Interrogation of mammalian protein complex structure, function, and membership using Genome-Scale fitness screens</article-title>. <source>Cell Syst</source><year>2018</year>;<volume>6</volume>:<fpage>555</fpage>–<lpage>68.e7</lpage>.<pub-id pub-id-type="pmid">29778836</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B22">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Robson</surname><given-names>M</given-names></string-name>, <string-name><surname>Goessl</surname><given-names>C</given-names></string-name>, <string-name><surname>Domchek</surname><given-names>S</given-names></string-name></person-group><etal>et al</etal><article-title>Olaparib for metastatic germline BRCA-mutated breast cancer</article-title>. <source>N Engl J Med</source><year>2017</year>;<volume>377</volume>:<fpage>1792</fpage>–<lpage>3</lpage>.</mixed-citation>
    </ref>
    <ref id="btad381-B23">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Robson</surname><given-names>ME</given-names></string-name>, <string-name><surname>Tung</surname><given-names>N</given-names></string-name>, <string-name><surname>Conte</surname><given-names>P</given-names></string-name></person-group><etal>et al</etal><article-title>OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer</article-title>. <source>Ann Oncol</source><year>2019</year>;<volume>30</volume>:<fpage>558</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="pmid">30689707</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B24">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shalem</surname><given-names>O</given-names></string-name>, <string-name><surname>Sanjana</surname><given-names>NE</given-names></string-name>, <string-name><surname>Hartenian</surname><given-names>E</given-names></string-name></person-group><etal>et al</etal><article-title>Genome-scale CRISPR-Cas9 knockout screening in human cells</article-title>. <source>Science</source><year>2014</year>;<volume>343</volume>:<fpage>84</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">24336571</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B25">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Takemon</surname><given-names>Y</given-names></string-name>, <string-name><surname>LeBlanc</surname><given-names>VG</given-names></string-name>, <string-name><surname>Song</surname><given-names>J</given-names></string-name></person-group><etal>et al</etal><article-title>Multi-omic analysis of CIC’s functional networks reveals novel interaction partners and a potential role in mitotic fidelity</article-title>. <source>Cancers</source><year>2023</year>;<volume>15</volume>:<fpage>2805</fpage>.</mixed-citation>
    </ref>
    <ref id="btad381-B26">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wainberg</surname><given-names>M</given-names></string-name>, <string-name><surname>Kamber</surname><given-names>RA</given-names></string-name>, <string-name><surname>Balsubramani</surname><given-names>A</given-names></string-name></person-group><etal>et al</etal><article-title>A genome-wide atlas of co-essential modules assigns function to uncharacterized genes</article-title>. <source>Nat Genet</source><year>2021</year>;<volume>53</volume>:<fpage>638</fpage>–<lpage>49</lpage>.<pub-id pub-id-type="pmid">33859415</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B27">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>T</given-names></string-name>, <string-name><surname>Yu</surname><given-names>H</given-names></string-name>, <string-name><surname>Hughes</surname><given-names>NW</given-names></string-name></person-group><etal>et al</etal><article-title>Gene essentiality profiling reveals gene networks and synthetic lethal interactions with oncogenic ras</article-title>. <source>Cell</source><year>2017</year>;<volume>168</volume>:<fpage>890</fpage>–<lpage>903.e15</lpage>.<pub-id pub-id-type="pmid">28162770</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Bioinformatics</journal-id>
    <journal-id journal-id-type="iso-abbrev">Bioinformatics</journal-id>
    <journal-id journal-id-type="publisher-id">bioinformatics</journal-id>
    <journal-title-group>
      <journal-title>Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1367-4803</issn>
    <issn pub-type="epub">1367-4811</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10284671</article-id>
    <article-id pub-id-type="pmid">37326978</article-id>
    <article-id pub-id-type="doi">10.1093/bioinformatics/btad381</article-id>
    <article-id pub-id-type="publisher-id">btad381</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Applications Note</subject>
        <subj-group subj-group-type="category-toc-heading">
          <subject>Systems Biology</subject>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI01060</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>GRETTA: an R package for mapping <italic toggle="yes">in silico</italic> genetic interaction and essentiality networks</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3538-4409</contrib-id>
        <name>
          <surname>Takemon</surname>
          <given-names>Yuka</given-names>
        </name>
        <aff><institution>Genome Science and Technology Graduate Program, University of British Columbia</institution>, Vancouver, BC V5Z 4S6, <country country="CA">Canada</country></aff>
        <aff><institution>Michael Smith Laboratories, University of British Columbia</institution>, Vancouver, BC V6T 1Z4, <country country="CA">Canada</country></aff>
        <aff><institution>Canada’s Michael Smith Genome Sciences Centre, BC Cancer Research Institute</institution>, Vancouver, BC V5Z 4S6, <country country="CA">Canada</country></aff>
        <!--ytakemon@bcgsc.ca-->
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7146-7175</contrib-id>
        <name>
          <surname>Marra</surname>
          <given-names>Marco A</given-names>
        </name>
        <aff><institution>Michael Smith Laboratories, University of British Columbia</institution>, Vancouver, BC V6T 1Z4, <country country="CA">Canada</country></aff>
        <aff><institution>Canada’s Michael Smith Genome Sciences Centre, BC Cancer Research Institute</institution>, Vancouver, BC V5Z 4S6, <country country="CA">Canada</country></aff>
        <aff><institution>Department of Medical Genetics, University of British Columbia</institution>, Vancouver, BC V6H 3N1, <country country="CA">Canada</country></aff>
        <!--mmarra@bcgsc.ca-->
        <xref rid="btad381-cor1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Kelso</surname>
          <given-names>Janet</given-names>
        </name>
        <role>Associate Editor</role>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="btad381-cor1">Corresponding author. Michael Smith Laboratories, University of British Columbia, 301-2185 East Mall, Vancouver, BC V6T 1Z4, Canada. E-mail: <email>mmarra@bcgsc.ca</email> (M.A.M.)</corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <month>6</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2023-06-16">
      <day>16</day>
      <month>6</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>16</day>
      <month>6</month>
      <year>2023</year>
    </pub-date>
    <volume>39</volume>
    <issue>6</issue>
    <elocation-id>btad381</elocation-id>
    <history>
      <date date-type="received">
        <day>21</day>
        <month>9</month>
        <year>2022</year>
      </date>
      <date date-type="rev-recd">
        <day>02</day>
        <month>6</month>
        <year>2023</year>
      </date>
      <date date-type="editorial-decision">
        <day>07</day>
        <month>6</month>
        <year>2023</year>
      </date>
      <date date-type="corrected-typeset">
        <day>21</day>
        <month>6</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2023. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2023</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="btad381.pdf"/>
    <abstract>
      <title>Abstract</title>
      <sec id="s1">
        <title>Summary</title>
        <p>Mapping genetic interactions and essentiality networks in human cell lines has been used to identify vulnerabilities of cells carrying specific genetic alterations and to associate novel functions to genes, respectively. <italic toggle="yes">In vitro</italic> and <italic toggle="yes">in vivo</italic> genetic screens to decipher these networks are resource-intensive, limiting the throughput of samples that can be analyzed. In this application note, we provide an R package we call Genetic inteRaction and EssenTiality neTwork mApper (GRETTA). GRETTA is an accessible tool for <italic toggle="yes">in silico</italic> genetic interaction screens and essentiality network analyses using publicly available data, requiring only basic R programming knowledge.</p>
      </sec>
      <sec id="s2">
        <title>Availability and implementation</title>
        <p>The R package, GRETTA, is licensed under GNU General Public License v3.0 and freely available at <ext-link xlink:href="https://github.com/ytakemon/GRETTA" ext-link-type="uri">https://github.com/ytakemon/GRETTA</ext-link> and <ext-link xlink:href="https://doi.org/10.5281/zenodo.6940757" ext-link-type="uri">https://doi.org/10.5281/zenodo.6940757</ext-link>, with documentation and tutorial. A Singularity container is also available at <ext-link xlink:href="https://cloud.sylabs.io/library/ytakemon/gretta/gretta" ext-link-type="uri">https://cloud.sylabs.io/library/ytakemon/gretta/gretta</ext-link>.</p>
      </sec>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Canadian Institutes of Health Research</institution>
            <institution-id institution-id-type="DOI">10.13039/501100000024</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>FDN-143288</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="4"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec>
    <title>1 Introduction</title>
    <p>Genetic perturbation screens, such as CRISPR-Cas9 knockout (KO) screens, have been used to uncover lethal and alleviating genetic interactions (GIs; <xref rid="btad381-B24" ref-type="bibr">Shalem <italic toggle="yes">et al.</italic> 2014</xref>, <xref rid="btad381-B11" ref-type="bibr">Hart <italic toggle="yes">et al.</italic> 2015</xref>, <xref rid="btad381-B27" ref-type="bibr">Wang <italic toggle="yes">et al.</italic> 2017</xref>, <xref rid="btad381-B1" ref-type="bibr">Behan <italic toggle="yes">et al.</italic> 2019</xref>) and essentiality networks to decipher a gene’s functional membership (<xref rid="btad381-B20" ref-type="bibr">Pan <italic toggle="yes">et al.</italic> 2018</xref>, <xref rid="btad381-B26" ref-type="bibr">Wainberg <italic toggle="yes">et al.</italic> 2021</xref>). Two genes are said to share a lethal, or synthetic lethal (SL), GI when the perturbation of both genes together in the same cell impedes cell viability, but perturbation of either gene individually has no impact on viability (<xref rid="btad381-B15" ref-type="bibr">Mani <italic toggle="yes">et al.</italic> 2008</xref>). Conversely, an alleviating GI occurs when the perturbation of two genes leads to a fitness advantage over cells with either gene perturbed individually (<xref rid="btad381-B15" ref-type="bibr">Mani <italic toggle="yes">et al.</italic> 2008</xref>). Lethal GIs of genes mutated in cancers have revealed tumor-specific vulnerabilities that can be therapeutically exploited. Most notable are the lethal GIs between <italic toggle="yes">BRCA1/2</italic> and <italic toggle="yes">PARP1</italic> (<xref rid="btad381-B4" ref-type="bibr">Bryant <italic toggle="yes">et al.</italic> 2005</xref>, <xref rid="btad381-B9" ref-type="bibr">Farmer <italic toggle="yes">et al.</italic> 2005</xref>), which led to the use of PARP inhibitors in BRCA1/2-deficient breast (<xref rid="btad381-B22" ref-type="bibr">Robson <italic toggle="yes">et al.</italic> 2017</xref>, <xref rid="btad381-B23" ref-type="bibr">2019</xref>), ovarian (<xref rid="btad381-B18" ref-type="bibr">Mirza <italic toggle="yes">et al.</italic> 2018</xref>), and prostate cancers (<xref rid="btad381-B21" ref-type="bibr">Ramakrishnan Geethakumari <italic toggle="yes">et al.</italic> 2017</xref>). Essentiality network maps have been utilized to assign novel functions to genes (<xref rid="btad381-B27" ref-type="bibr">Wang <italic toggle="yes">et al.</italic> 2017</xref>, <xref rid="btad381-B14" ref-type="bibr">Kim <italic toggle="yes">et al.</italic> 2019</xref>, <xref rid="btad381-B26" ref-type="bibr">Wainberg <italic toggle="yes">et al.</italic> 2021</xref>, <xref rid="btad381-B20" ref-type="bibr">Pan <italic toggle="yes">et al.</italic> 2018</xref>). Two genes share co-essentiality when perturbation of either gene leads to similar fitness effects in cells. This is interpreted to indicate that the genes may have similar or synergistic functions (<xref rid="btad381-B14" ref-type="bibr">Kim <italic toggle="yes">et al.</italic> 2019</xref>, <xref rid="btad381-B26" ref-type="bibr">Wainberg <italic toggle="yes">et al.</italic> 2021</xref>). In contrast, two genes are antiessential when perturbations in either of them lead to opposite cellular fitness effects. This is interpreted to indicate genes with inhibitory or antagonistic relationships (<xref rid="btad381-B14" ref-type="bibr">Kim <italic toggle="yes">et al.</italic> 2019</xref>, <xref rid="btad381-B26" ref-type="bibr">Wainberg <italic toggle="yes">et al.</italic> 2021</xref>). It seems clear that mapping GI and essentiality networks of cancer-associated genes could reveal biological functions that might be leveraged to inform potential therapeutic strategies.</p>
    <p>The Cancer Dependency Map (DepMap) public data platform (<xref rid="btad381-B17" ref-type="bibr">Meyers <italic toggle="yes">et al.</italic> 2017</xref>, <xref rid="btad381-B10" ref-type="bibr">Ghandi <italic toggle="yes">et al.</italic> 2019</xref>) is the largest resource for mining GIs and essentiality networks of human cancer cell lines. DepMap contains data from multi-omic characterization of cancer cell lines, including whole-genome sequencing, exome sequencing, RNA sequencing (RNA-seq) (<xref rid="btad381-B10" ref-type="bibr">Ghandi <italic toggle="yes">et al.</italic> 2019</xref>), proteomic quantification (<xref rid="btad381-B19" ref-type="bibr">Nusinow <italic toggle="yes">et al.</italic> 2020</xref>), and genome-wide CRISPR-Cas9 KO screens (<xref rid="btad381-B17" ref-type="bibr">Meyers <italic toggle="yes">et al.</italic> 2017</xref>), which are updated bi-annually with additional cancer cell lines (detailed in <ext-link xlink:href="https://depmap.org/portal/announcements/" ext-link-type="uri">https://depmap.org/portal/announcements/</ext-link>). Novel algorithms utilizing DepMap data to predict GIs have emerged (<xref rid="btad381-B8" ref-type="bibr">De Kegel <italic toggle="yes">et al.</italic> 2021</xref>, <xref rid="btad381-B5" ref-type="bibr">Chiu <italic toggle="yes">et al.</italic> 2021</xref>, <xref rid="btad381-B2" ref-type="bibr">Benfatto <italic toggle="yes">et al.</italic> 2021</xref>). However, these tools either lack flexibility, the ability to detect alleviating GIs, or require advanced programming knowledge. Thus, for various reasons, these tools have limited accessibility to the larger research community.</p>
    <p>To facilitate discoveries using GI and essentiality network mapping, we created an R package called Genetic inteRaction and EssenTiality neTwork mApper (GRETTA), which leverages the DepMap data platform. GRETTA provides a simplified approach to query DepMap for user-defined cell line features, including selection by gene, mutation, and cancer types, to predict both lethal and alleviating GIs and essentiality networks. We provide an intuitive method for visualizing results that require only a basic understanding of the R programming language. In addition to the case study, we provide here, we have used GRETTA to reveal functional networks of CIC, a cancer-associated gene (<xref rid="btad381-B25" ref-type="bibr">Takemon <italic toggle="yes">et al.</italic> 2023</xref>). We have thus demonstrated the utility of our tool for discovering genetic interaction and essentiality networks.</p>
  </sec>
  <sec>
    <title>2 Materials and methods</title>
    <sec>
      <title>2.1 Performing <italic toggle="yes">in silico</italic> GI screens</title>
      <p>GRETTA leverages cell line annotations, mutation annotations, copy number quantifications, RNA-seq, proteomic quantifications, and genome-wide CRISPR-Cas9 KO screen data that were made available by the DepMap data platform (<xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref>; <xref rid="btad381-B17" ref-type="bibr">Meyers <italic toggle="yes">et al.</italic> 2017</xref>, <xref rid="btad381-B10" ref-type="bibr">Ghandi <italic toggle="yes">et al.</italic> 2019</xref>, <xref rid="btad381-B19" ref-type="bibr">Nusinow <italic toggle="yes">et al.</italic> 2020</xref>) and predicts candidate GIs in three steps: (i) selecting control and mutant cancer cell lines; (ii) surveying mRNA and/or protein expression changes; and (iii) predicting and visualizing GIs (illustrated in <xref rid="btad381-F1" ref-type="fig">Fig. 1</xref> with a detailed version provided in <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S1A</xref>). Briefly, the first step is driven by a user-defined feature, such as a gene of interest (GOI). By default, when a GOI is provided, all pan-cancer cell lines with wildtype (WT) alleles and neutral copy number of the GOI are assigned to the control group, and lines with loss-of-function alterations in the GOI are assigned to one of the mutant subgroups, including homozygous deletion (HomDel), trans-heterozygous deletion, and heterozygous deletion groups (see <xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref> for details). Cell lines can also be selected by specific mutation, cancer type, or manual curation (<xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref>).</p>
      <fig position="float" id="btad381-F1">
        <label>Figure 1</label>
        <caption>
          <p>An overview of <italic toggle="yes">in silico</italic> GI screening and essentiality mapping using GRETTA. Top panel: A user defines a GOI and/or a cancer type to map GI or essentiality networks. When a cancer type is not defined, GRETTA defaults to a pan-cancer GI screen or essentiality mapping. Left panel: A three-step workflow to predict and visualize candidate GIs of a user-defined GOI in the defined cancer type. After cell lines are grouped into control or mutant groups, the user must select one mutant group based on gene and protein expression phenotypes. The genome-wide KO screen data for this user-selected mutant cell line group are then compared to those of the control group to predict lethal and alleviating GIs. Right panel: Pearson correlation analyses are performed between the KO effect scores of the GOI and each gene that was targeted in DepMap’s genome-wide screen (18 333 genes). The thresholds used to determine co-/antiessential genes are partly determined using inflection points of the ranked positive and negative coefficient curves. A detailed description of the workflow is provided in <xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref>. The DepMap data type processed at each step is illustrated in each subheading and noted in the legend. This figure was partly created with BioRender.com.</p>
        </caption>
        <graphic xlink:href="btad381f1" position="float"/>
      </fig>
      <p>The second step involves extracting DepMap mRNA and protein expression data (if available) and performing differential mRNA and protein expression analyses of the GOI between control cell lines and mutant cell lines (<xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref>). A mutant group with a significant reduction in mRNA or protein expression compared to the control group by Welch’s <italic toggle="yes">t</italic>-test is consistent with a potential reduction of GOI functions, and thus a user may select such a mutant cell line group for downstream analysis.</p>
      <p>Finally, candidate GIs are predicted by conducting differential lethality probability analyses, which identify a gene KO that results in opposing survival outcomes in the mutant cell lines and control cell lines. Mann–Whitney <italic toggle="yes">U</italic> tests are performed by extracting the lethality probabilities of each of the 18 333 genes that were targeted in the DepMap CRISPR-Cas9 KO screen and comparing the control and mutant cancer cell line groups. Optionally, at this step, a list of genes can be provided to perform a small-scale screen. GRETTA also generates an interaction score that is used to visualize candidate GIs and to rank them from most to least likely to be lethal or alleviating (<xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref>).</p>
    </sec>
    <sec>
      <title>2.2 Mapping essentiality networks</title>
      <p>GRETTA adapted a previously published Pearson correlation-based method for mapping essentiality between genes (<xref rid="btad381-B27" ref-type="bibr">Wang <italic toggle="yes">et al.</italic> 2017</xref>, <xref rid="btad381-B20" ref-type="bibr">Pan <italic toggle="yes">et al.</italic> 2018</xref>, <xref rid="btad381-B14" ref-type="bibr">Kim <italic toggle="yes">et al.</italic> 2019</xref>; illustrated in <xref rid="btad381-F1" ref-type="fig">Fig. 1</xref>, <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S1A</xref>; see <xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref> for detailed description). Briefly, the genome-wide CRISPR-Cas9 KO screen data from DepMap is used to calculate pan-cancer essentiality of a gene in the following steps. First, KO effect scores of GOIs (a user-defined input) are extracted from all screened cancer cell lines. Next, Pearson’s correlation coefficients and <italic toggle="yes">P</italic>-values are calculated between the KO effect scores of the GOIs and 18 333 genes screened in the dataset. Next, the inflection point of the ranked positive and negative coefficient score curves is calculated to determine a threshold to identify co-essential (positively correlated) and antiessential (negatively correlated) genes. Finally, a ranked correlation coefficient score is provided as an output and is used to visualize essentiality networks.</p>
    </sec>
  </sec>
  <sec>
    <title>3 Case study: predicting pan-cancer GIs and co-essentiality networks of <italic toggle="yes">ARID1A</italic></title>
    <p><italic toggle="yes">ARID1A</italic> is a member of the mammalian switch/sucrose non-fermentable (SWI/SNF) complex (<xref rid="btad381-B16" ref-type="bibr">Mashtalir <italic toggle="yes">et al.</italic> 2018</xref>) with a known SL GI to its paralog <italic toggle="yes">ARID1B</italic> (<xref rid="btad381-B13" ref-type="bibr">Helming <italic toggle="yes">et al.</italic> 2014</xref>). Rationalizing that this known SL interaction and complex association would serve as positive controls, we applied GRETTA to predict pan-cancer GIs and essentiality networks of <italic toggle="yes">ARID1A</italic>, expecting to replicate known interactors and co-essential genes, respectively. We identified an <italic toggle="yes">ARID1A</italic> WT control group and an <italic toggle="yes">ARID1A</italic> HomDel mutant group, consisting of 906 and 23 cell lines, respectively. The <italic toggle="yes">ARID1A</italic> HomDel mutant group showed significantly reduced <italic toggle="yes">ARID1A</italic> mRNA expression compared to the control group (Welch’s <italic toggle="yes">t</italic>-test <italic toggle="yes">P</italic> &lt;.05; <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S2A</xref> and <xref rid="sup1" ref-type="supplementary-material">B</xref> and <xref rid="sup1" ref-type="supplementary-material">Table S1A</xref> and <xref rid="sup1" ref-type="supplementary-material">B</xref>), consistent with potentially reduced ARID1A function. Using these two groups, we found that <italic toggle="yes">ARID1B</italic> was predicted to be the top lethal genetic interactor of <italic toggle="yes">ARID1A</italic> (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S2C</xref> and <xref rid="sup1" ref-type="supplementary-material">Table S1C</xref>), thus confirming the established SL GI between these two genes. Furthermore, a pan-cancer essentiality analysis of <italic toggle="yes">ARID1A</italic> revealed the expected top five list of co-essential genes that are known mSWI/SNF complex members, namely <italic toggle="yes">ARID1A, SMARCB1</italic>, <italic toggle="yes">SMARCE1</italic>, <italic toggle="yes">SMARCC1</italic>, and <italic toggle="yes">SS18</italic> (<xref rid="btad381-B16" ref-type="bibr">Mashtalir <italic toggle="yes">et al.</italic> 2018</xref>; <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S2D</xref> and <xref rid="sup1" ref-type="supplementary-material">Table S1D</xref>). GRETTA was thus able to recapitulate known GIs and co-essential networks of <italic toggle="yes">ARID1A</italic>.</p>
  </sec>
  <sec>
    <title>4 Discussion</title>
    <p>GRETTA was built to provide an easy-to-use method for mapping GI and essentiality networks. The R package requires only a basic understanding of the R programming language and we provide an easy-to-follow tutorial (<ext-link xlink:href="https://github.com/ytakemon/GRETTA" ext-link-type="uri">https://github.com/ytakemon/GRETTA</ext-link>). Using GRETTA, we replicated known GIs and essentiality networks of ARID1A, thus demonstrating how the tool can be used and ultimately applied to discover GI and essentiality networks of other GOI. We are currently aware of 365 visitors and 135 total unique installations of GRETTA and from this deduce that GRETTA is of interest to the wider research community.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>btad381_Supplementary_Data</label>
      <media xlink:href="btad381_supplementary_data.zip">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ack1">
    <title>Acknowledgements</title>
    <p>We would like to acknowledge the Broad Institute for generating and making their DepMap data platform available for the research community. We would like to thank Drs Anindya Dutta and Yoshiyuki Shibata at the University of Alabama at Birmingham Marnix E. Heersink School of Medicine for testing GRETTA and for the discussions that helped improve its documentation. We would also like to thank Richard Corbett at Canada’s Michael Smith Genome Sciences Centre for the discussion and guidance on containerizing the tool for reproducibility.</p>
  </ack>
  <sec>
    <title>Supplementary data</title>
    <p><xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> is available at <italic toggle="yes">Bioinformatics</italic> online.</p>
  </sec>
  <sec sec-type="COI-statement">
    <title>Conflict of interest</title>
    <p>None declared.</p>
  </sec>
  <sec>
    <title>Funding</title>
    <p>This work was supported by the Canadian Institutes of Health Research (CIHR; FDN-143288) and the Canada Research Chairs to M.A.M.; and the University of British Columbia (UBC) Four-year fellowships (6456, 6569), UBC International Student Award (4884), and UBC President’s Academic Excellence Initiative PhD Award (6817) to Y.T.</p>
  </sec>
  <sec sec-type="data-availability">
    <title>Data availability</title>
    <p>The GRETTA R package, data analyzed in this study (DepMap version 22Q2), and the code used to generate the supplementary figures and tables are publicly available as a tutorial provided on the GRETTA GitHub repository (<ext-link xlink:href="https://github.com/ytakemon/GRETTA" ext-link-type="uri">https://github.com/ytakemon/GRETTA</ext-link>). GRETTA has been archived with a citable DOI on Zenodo (<ext-link xlink:href="https://doi.org/10.5281/zenodo.6940757" ext-link-type="uri">https://doi.org/10.5281/zenodo.6940757</ext-link>) and a Singularity container has been made available on Sylabs (<ext-link xlink:href="https://cloud.sylabs.io/library/ytakemon/gretta/gretta" ext-link-type="uri">https://cloud.sylabs.io/library/ytakemon/gretta/gretta</ext-link>) to ensure reproducibility. GRETTA is shared under the GNU General Public License v3.0.</p>
  </sec>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="btad381-B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Behan</surname><given-names>FM</given-names></string-name>, <string-name><surname>Iorio</surname><given-names>F</given-names></string-name>, <string-name><surname>Picco</surname><given-names>G</given-names></string-name></person-group><etal>et al</etal><article-title>Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens</article-title>. <source>Nature</source><year>2019</year>;<volume>568</volume>:<fpage>511</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">30971826</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Benfatto</surname><given-names>S</given-names></string-name>, <string-name><surname>Serçin</surname><given-names>Ö</given-names></string-name>, <string-name><surname>Dejure</surname><given-names>FR</given-names></string-name></person-group><etal>et al</etal><article-title>Uncovering cancer vulnerabilities by machine learning prediction of synthetic lethality</article-title>. <source>Mol Cancer</source><year>2021</year>;<volume>20</volume>:<fpage>111</fpage>.<pub-id pub-id-type="pmid">34454516</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B4">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bryant</surname><given-names>HE</given-names></string-name>, <string-name><surname>Schultz</surname><given-names>N</given-names></string-name>, <string-name><surname>Thomas</surname><given-names>HD</given-names></string-name></person-group><etal>et al</etal><article-title>Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase</article-title>. <source>Nature</source><year>2005</year>;<volume>434</volume>:<fpage>913</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">15829966</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chiu</surname><given-names>Y-C</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>S</given-names></string-name>, <string-name><surname>Wang</surname><given-names>L-J</given-names></string-name></person-group><etal>et al</etal><article-title>Predicting and characterizing a cancer dependency map of tumors with deep learning</article-title>. <source>Sci Adv</source><year>2021</year>;<volume>7</volume>:eabh1275.</mixed-citation>
    </ref>
    <ref id="btad381-B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>De Kegel</surname><given-names>B</given-names></string-name>, <string-name><surname>Quinn</surname><given-names>N</given-names></string-name>, <string-name><surname>Thompson</surname><given-names>NA</given-names></string-name></person-group><etal>et al</etal><article-title>Comprehensive prediction of robust synthetic lethality between paralog pairs in cancer cell lines</article-title>. <source>Cell Syst</source><year>2021</year>;<volume>12</volume>:<fpage>1144</fpage>–<lpage>59.e6</lpage>. <pub-id pub-id-type="doi">10.1016/j.cels.2021.08.006</pub-id>.<pub-id pub-id-type="pmid">34529928</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B9">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Farmer</surname><given-names>H</given-names></string-name>, <string-name><surname>McCabe</surname><given-names>N</given-names></string-name>, <string-name><surname>Lord</surname><given-names>CJ</given-names></string-name></person-group><etal>et al</etal><article-title>Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</article-title>. <source>Nature</source><year>2005</year>;<volume>434</volume>:<fpage>917</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">15829967</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B21">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Geethakumari</surname><given-names>PR</given-names></string-name>, <string-name><surname>Schiewer</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Knudsen</surname><given-names>KE</given-names></string-name></person-group><etal>et al</etal><article-title>PARP inhibitors in prostate cancer</article-title>. <source>Curr Treat Options Oncol</source><year>2017</year>;<volume>18</volume>:<fpage>37</fpage>.<pub-id pub-id-type="pmid">28540598</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ghandi</surname><given-names>M</given-names></string-name>, <string-name><surname>Huang</surname><given-names>FW</given-names></string-name>, <string-name><surname>Jané-Valbuena</surname><given-names>J</given-names></string-name></person-group><etal>et al</etal><article-title>Next-generation characterization of the cancer cell line encyclopedia</article-title>. <source>Nature</source><year>2019</year>;<volume>569</volume>:<fpage>503</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">31068700</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hart</surname><given-names>T</given-names></string-name>, <string-name><surname>Chandrashekhar</surname><given-names>M</given-names></string-name>, <string-name><surname>Aregger</surname><given-names>M</given-names></string-name></person-group><etal>et al</etal><article-title>High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities</article-title>. <source>Cell</source><year>2015</year>;<volume>163</volume>:<fpage>1515</fpage>–<lpage>26</lpage>.<pub-id pub-id-type="pmid">26627737</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Helming</surname><given-names>KC</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>BG</given-names></string-name></person-group><etal>et al</etal><article-title>ARID1B is a specific vulnerability in ARID1A-mutant cancers</article-title>. <source>Nat Med</source><year>2014</year>;<volume>20</volume>:<fpage>251</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">24562383</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B14">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname><given-names>E</given-names></string-name>, <string-name><surname>Dede</surname><given-names>M</given-names></string-name>, <string-name><surname>Lenoir</surname><given-names>WF</given-names></string-name></person-group><etal>et al</etal><article-title>A network of human functional gene interactions from knockout fitness screens in cancer cells</article-title>. <source>Life Sci Alliance</source><year>2019</year>;<volume>2</volume>:<fpage>e201800278</fpage>.<pub-id pub-id-type="pmid">30979825</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B15">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mani</surname><given-names>R</given-names></string-name>, <string-name><surname>St Onge</surname><given-names>RP</given-names></string-name>, <string-name><surname>Hartman</surname><given-names>JL</given-names></string-name></person-group><etal>et al</etal><article-title>Defining genetic interaction</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2008</year>;<volume>105</volume>:<fpage>3461</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">18305163</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mashtalir</surname><given-names>N</given-names></string-name>, <string-name><surname>D'Avino</surname><given-names>AR</given-names></string-name>, <string-name><surname>Michel</surname><given-names>BC</given-names></string-name></person-group><etal>et al</etal><article-title>Modular organization and assembly of SWI/SNF family chromatin remodeling complexes</article-title>. <source>Cell</source><year>2018</year>;<volume>175</volume>:<fpage>1272</fpage>–<lpage>88.e20</lpage>.<pub-id pub-id-type="pmid">30343899</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B17">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Meyers</surname><given-names>RM</given-names></string-name>, <string-name><surname>Bryan</surname><given-names>JG</given-names></string-name>, <string-name><surname>McFarland</surname><given-names>JM</given-names></string-name></person-group><etal>et al</etal><article-title>Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells</article-title>. <source>Nat Genet</source><year>2017</year>;<volume>49</volume>:<fpage>1779</fpage>–<lpage>84</lpage>.<pub-id pub-id-type="pmid">29083409</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B18">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mirza</surname><given-names>MR</given-names></string-name>, <string-name><surname>Pignata</surname><given-names>S</given-names></string-name>, <string-name><surname>Ledermann</surname><given-names>JA</given-names></string-name></person-group><etal>et al</etal><article-title>Latest clinical evidence and further development of PARP inhibitors in ovarian cancer</article-title>. <source>Ann Oncol</source><year>2018</year>;<volume>29</volume>:<fpage>1366</fpage>–<lpage>76</lpage>.<pub-id pub-id-type="pmid">29750420</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B19">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nusinow</surname><given-names>DP</given-names></string-name>, <string-name><surname>Szpyt</surname><given-names>J</given-names></string-name>, <string-name><surname>Ghandi</surname><given-names>M</given-names></string-name></person-group><etal>et al</etal><article-title>Quantitative proteomics of the cancer cell line encyclopedia</article-title>. <source>Cell</source><year>2020</year>;<volume>180</volume>:<fpage>387</fpage>–<lpage>402.e16</lpage>.<pub-id pub-id-type="pmid">31978347</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B20">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pan</surname><given-names>J</given-names></string-name>, <string-name><surname>Meyers</surname><given-names>RM</given-names></string-name>, <string-name><surname>Michel</surname><given-names>BC</given-names></string-name></person-group><etal>et al</etal><article-title>Interrogation of mammalian protein complex structure, function, and membership using Genome-Scale fitness screens</article-title>. <source>Cell Syst</source><year>2018</year>;<volume>6</volume>:<fpage>555</fpage>–<lpage>68.e7</lpage>.<pub-id pub-id-type="pmid">29778836</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B22">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Robson</surname><given-names>M</given-names></string-name>, <string-name><surname>Goessl</surname><given-names>C</given-names></string-name>, <string-name><surname>Domchek</surname><given-names>S</given-names></string-name></person-group><etal>et al</etal><article-title>Olaparib for metastatic germline BRCA-mutated breast cancer</article-title>. <source>N Engl J Med</source><year>2017</year>;<volume>377</volume>:<fpage>1792</fpage>–<lpage>3</lpage>.</mixed-citation>
    </ref>
    <ref id="btad381-B23">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Robson</surname><given-names>ME</given-names></string-name>, <string-name><surname>Tung</surname><given-names>N</given-names></string-name>, <string-name><surname>Conte</surname><given-names>P</given-names></string-name></person-group><etal>et al</etal><article-title>OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer</article-title>. <source>Ann Oncol</source><year>2019</year>;<volume>30</volume>:<fpage>558</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="pmid">30689707</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B24">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shalem</surname><given-names>O</given-names></string-name>, <string-name><surname>Sanjana</surname><given-names>NE</given-names></string-name>, <string-name><surname>Hartenian</surname><given-names>E</given-names></string-name></person-group><etal>et al</etal><article-title>Genome-scale CRISPR-Cas9 knockout screening in human cells</article-title>. <source>Science</source><year>2014</year>;<volume>343</volume>:<fpage>84</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">24336571</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B25">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Takemon</surname><given-names>Y</given-names></string-name>, <string-name><surname>LeBlanc</surname><given-names>VG</given-names></string-name>, <string-name><surname>Song</surname><given-names>J</given-names></string-name></person-group><etal>et al</etal><article-title>Multi-omic analysis of CIC’s functional networks reveals novel interaction partners and a potential role in mitotic fidelity</article-title>. <source>Cancers</source><year>2023</year>;<volume>15</volume>:<fpage>2805</fpage>.</mixed-citation>
    </ref>
    <ref id="btad381-B26">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wainberg</surname><given-names>M</given-names></string-name>, <string-name><surname>Kamber</surname><given-names>RA</given-names></string-name>, <string-name><surname>Balsubramani</surname><given-names>A</given-names></string-name></person-group><etal>et al</etal><article-title>A genome-wide atlas of co-essential modules assigns function to uncharacterized genes</article-title>. <source>Nat Genet</source><year>2021</year>;<volume>53</volume>:<fpage>638</fpage>–<lpage>49</lpage>.<pub-id pub-id-type="pmid">33859415</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B27">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>T</given-names></string-name>, <string-name><surname>Yu</surname><given-names>H</given-names></string-name>, <string-name><surname>Hughes</surname><given-names>NW</given-names></string-name></person-group><etal>et al</etal><article-title>Gene essentiality profiling reveals gene networks and synthetic lethal interactions with oncogenic ras</article-title>. <source>Cell</source><year>2017</year>;<volume>168</volume>:<fpage>890</fpage>–<lpage>903.e15</lpage>.<pub-id pub-id-type="pmid">28162770</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Bioinformatics</journal-id>
    <journal-id journal-id-type="iso-abbrev">Bioinformatics</journal-id>
    <journal-id journal-id-type="publisher-id">bioinformatics</journal-id>
    <journal-title-group>
      <journal-title>Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1367-4803</issn>
    <issn pub-type="epub">1367-4811</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10284671</article-id>
    <article-id pub-id-type="pmid">37326978</article-id>
    <article-id pub-id-type="doi">10.1093/bioinformatics/btad381</article-id>
    <article-id pub-id-type="publisher-id">btad381</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Applications Note</subject>
        <subj-group subj-group-type="category-toc-heading">
          <subject>Systems Biology</subject>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI01060</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>GRETTA: an R package for mapping <italic toggle="yes">in silico</italic> genetic interaction and essentiality networks</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3538-4409</contrib-id>
        <name>
          <surname>Takemon</surname>
          <given-names>Yuka</given-names>
        </name>
        <aff><institution>Genome Science and Technology Graduate Program, University of British Columbia</institution>, Vancouver, BC V5Z 4S6, <country country="CA">Canada</country></aff>
        <aff><institution>Michael Smith Laboratories, University of British Columbia</institution>, Vancouver, BC V6T 1Z4, <country country="CA">Canada</country></aff>
        <aff><institution>Canada’s Michael Smith Genome Sciences Centre, BC Cancer Research Institute</institution>, Vancouver, BC V5Z 4S6, <country country="CA">Canada</country></aff>
        <!--ytakemon@bcgsc.ca-->
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7146-7175</contrib-id>
        <name>
          <surname>Marra</surname>
          <given-names>Marco A</given-names>
        </name>
        <aff><institution>Michael Smith Laboratories, University of British Columbia</institution>, Vancouver, BC V6T 1Z4, <country country="CA">Canada</country></aff>
        <aff><institution>Canada’s Michael Smith Genome Sciences Centre, BC Cancer Research Institute</institution>, Vancouver, BC V5Z 4S6, <country country="CA">Canada</country></aff>
        <aff><institution>Department of Medical Genetics, University of British Columbia</institution>, Vancouver, BC V6H 3N1, <country country="CA">Canada</country></aff>
        <!--mmarra@bcgsc.ca-->
        <xref rid="btad381-cor1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Kelso</surname>
          <given-names>Janet</given-names>
        </name>
        <role>Associate Editor</role>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="btad381-cor1">Corresponding author. Michael Smith Laboratories, University of British Columbia, 301-2185 East Mall, Vancouver, BC V6T 1Z4, Canada. E-mail: <email>mmarra@bcgsc.ca</email> (M.A.M.)</corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <month>6</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2023-06-16">
      <day>16</day>
      <month>6</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>16</day>
      <month>6</month>
      <year>2023</year>
    </pub-date>
    <volume>39</volume>
    <issue>6</issue>
    <elocation-id>btad381</elocation-id>
    <history>
      <date date-type="received">
        <day>21</day>
        <month>9</month>
        <year>2022</year>
      </date>
      <date date-type="rev-recd">
        <day>02</day>
        <month>6</month>
        <year>2023</year>
      </date>
      <date date-type="editorial-decision">
        <day>07</day>
        <month>6</month>
        <year>2023</year>
      </date>
      <date date-type="corrected-typeset">
        <day>21</day>
        <month>6</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2023. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2023</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="btad381.pdf"/>
    <abstract>
      <title>Abstract</title>
      <sec id="s1">
        <title>Summary</title>
        <p>Mapping genetic interactions and essentiality networks in human cell lines has been used to identify vulnerabilities of cells carrying specific genetic alterations and to associate novel functions to genes, respectively. <italic toggle="yes">In vitro</italic> and <italic toggle="yes">in vivo</italic> genetic screens to decipher these networks are resource-intensive, limiting the throughput of samples that can be analyzed. In this application note, we provide an R package we call Genetic inteRaction and EssenTiality neTwork mApper (GRETTA). GRETTA is an accessible tool for <italic toggle="yes">in silico</italic> genetic interaction screens and essentiality network analyses using publicly available data, requiring only basic R programming knowledge.</p>
      </sec>
      <sec id="s2">
        <title>Availability and implementation</title>
        <p>The R package, GRETTA, is licensed under GNU General Public License v3.0 and freely available at <ext-link xlink:href="https://github.com/ytakemon/GRETTA" ext-link-type="uri">https://github.com/ytakemon/GRETTA</ext-link> and <ext-link xlink:href="https://doi.org/10.5281/zenodo.6940757" ext-link-type="uri">https://doi.org/10.5281/zenodo.6940757</ext-link>, with documentation and tutorial. A Singularity container is also available at <ext-link xlink:href="https://cloud.sylabs.io/library/ytakemon/gretta/gretta" ext-link-type="uri">https://cloud.sylabs.io/library/ytakemon/gretta/gretta</ext-link>.</p>
      </sec>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Canadian Institutes of Health Research</institution>
            <institution-id institution-id-type="DOI">10.13039/501100000024</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>FDN-143288</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="4"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec>
    <title>1 Introduction</title>
    <p>Genetic perturbation screens, such as CRISPR-Cas9 knockout (KO) screens, have been used to uncover lethal and alleviating genetic interactions (GIs; <xref rid="btad381-B24" ref-type="bibr">Shalem <italic toggle="yes">et al.</italic> 2014</xref>, <xref rid="btad381-B11" ref-type="bibr">Hart <italic toggle="yes">et al.</italic> 2015</xref>, <xref rid="btad381-B27" ref-type="bibr">Wang <italic toggle="yes">et al.</italic> 2017</xref>, <xref rid="btad381-B1" ref-type="bibr">Behan <italic toggle="yes">et al.</italic> 2019</xref>) and essentiality networks to decipher a gene’s functional membership (<xref rid="btad381-B20" ref-type="bibr">Pan <italic toggle="yes">et al.</italic> 2018</xref>, <xref rid="btad381-B26" ref-type="bibr">Wainberg <italic toggle="yes">et al.</italic> 2021</xref>). Two genes are said to share a lethal, or synthetic lethal (SL), GI when the perturbation of both genes together in the same cell impedes cell viability, but perturbation of either gene individually has no impact on viability (<xref rid="btad381-B15" ref-type="bibr">Mani <italic toggle="yes">et al.</italic> 2008</xref>). Conversely, an alleviating GI occurs when the perturbation of two genes leads to a fitness advantage over cells with either gene perturbed individually (<xref rid="btad381-B15" ref-type="bibr">Mani <italic toggle="yes">et al.</italic> 2008</xref>). Lethal GIs of genes mutated in cancers have revealed tumor-specific vulnerabilities that can be therapeutically exploited. Most notable are the lethal GIs between <italic toggle="yes">BRCA1/2</italic> and <italic toggle="yes">PARP1</italic> (<xref rid="btad381-B4" ref-type="bibr">Bryant <italic toggle="yes">et al.</italic> 2005</xref>, <xref rid="btad381-B9" ref-type="bibr">Farmer <italic toggle="yes">et al.</italic> 2005</xref>), which led to the use of PARP inhibitors in BRCA1/2-deficient breast (<xref rid="btad381-B22" ref-type="bibr">Robson <italic toggle="yes">et al.</italic> 2017</xref>, <xref rid="btad381-B23" ref-type="bibr">2019</xref>), ovarian (<xref rid="btad381-B18" ref-type="bibr">Mirza <italic toggle="yes">et al.</italic> 2018</xref>), and prostate cancers (<xref rid="btad381-B21" ref-type="bibr">Ramakrishnan Geethakumari <italic toggle="yes">et al.</italic> 2017</xref>). Essentiality network maps have been utilized to assign novel functions to genes (<xref rid="btad381-B27" ref-type="bibr">Wang <italic toggle="yes">et al.</italic> 2017</xref>, <xref rid="btad381-B14" ref-type="bibr">Kim <italic toggle="yes">et al.</italic> 2019</xref>, <xref rid="btad381-B26" ref-type="bibr">Wainberg <italic toggle="yes">et al.</italic> 2021</xref>, <xref rid="btad381-B20" ref-type="bibr">Pan <italic toggle="yes">et al.</italic> 2018</xref>). Two genes share co-essentiality when perturbation of either gene leads to similar fitness effects in cells. This is interpreted to indicate that the genes may have similar or synergistic functions (<xref rid="btad381-B14" ref-type="bibr">Kim <italic toggle="yes">et al.</italic> 2019</xref>, <xref rid="btad381-B26" ref-type="bibr">Wainberg <italic toggle="yes">et al.</italic> 2021</xref>). In contrast, two genes are antiessential when perturbations in either of them lead to opposite cellular fitness effects. This is interpreted to indicate genes with inhibitory or antagonistic relationships (<xref rid="btad381-B14" ref-type="bibr">Kim <italic toggle="yes">et al.</italic> 2019</xref>, <xref rid="btad381-B26" ref-type="bibr">Wainberg <italic toggle="yes">et al.</italic> 2021</xref>). It seems clear that mapping GI and essentiality networks of cancer-associated genes could reveal biological functions that might be leveraged to inform potential therapeutic strategies.</p>
    <p>The Cancer Dependency Map (DepMap) public data platform (<xref rid="btad381-B17" ref-type="bibr">Meyers <italic toggle="yes">et al.</italic> 2017</xref>, <xref rid="btad381-B10" ref-type="bibr">Ghandi <italic toggle="yes">et al.</italic> 2019</xref>) is the largest resource for mining GIs and essentiality networks of human cancer cell lines. DepMap contains data from multi-omic characterization of cancer cell lines, including whole-genome sequencing, exome sequencing, RNA sequencing (RNA-seq) (<xref rid="btad381-B10" ref-type="bibr">Ghandi <italic toggle="yes">et al.</italic> 2019</xref>), proteomic quantification (<xref rid="btad381-B19" ref-type="bibr">Nusinow <italic toggle="yes">et al.</italic> 2020</xref>), and genome-wide CRISPR-Cas9 KO screens (<xref rid="btad381-B17" ref-type="bibr">Meyers <italic toggle="yes">et al.</italic> 2017</xref>), which are updated bi-annually with additional cancer cell lines (detailed in <ext-link xlink:href="https://depmap.org/portal/announcements/" ext-link-type="uri">https://depmap.org/portal/announcements/</ext-link>). Novel algorithms utilizing DepMap data to predict GIs have emerged (<xref rid="btad381-B8" ref-type="bibr">De Kegel <italic toggle="yes">et al.</italic> 2021</xref>, <xref rid="btad381-B5" ref-type="bibr">Chiu <italic toggle="yes">et al.</italic> 2021</xref>, <xref rid="btad381-B2" ref-type="bibr">Benfatto <italic toggle="yes">et al.</italic> 2021</xref>). However, these tools either lack flexibility, the ability to detect alleviating GIs, or require advanced programming knowledge. Thus, for various reasons, these tools have limited accessibility to the larger research community.</p>
    <p>To facilitate discoveries using GI and essentiality network mapping, we created an R package called Genetic inteRaction and EssenTiality neTwork mApper (GRETTA), which leverages the DepMap data platform. GRETTA provides a simplified approach to query DepMap for user-defined cell line features, including selection by gene, mutation, and cancer types, to predict both lethal and alleviating GIs and essentiality networks. We provide an intuitive method for visualizing results that require only a basic understanding of the R programming language. In addition to the case study, we provide here, we have used GRETTA to reveal functional networks of CIC, a cancer-associated gene (<xref rid="btad381-B25" ref-type="bibr">Takemon <italic toggle="yes">et al.</italic> 2023</xref>). We have thus demonstrated the utility of our tool for discovering genetic interaction and essentiality networks.</p>
  </sec>
  <sec>
    <title>2 Materials and methods</title>
    <sec>
      <title>2.1 Performing <italic toggle="yes">in silico</italic> GI screens</title>
      <p>GRETTA leverages cell line annotations, mutation annotations, copy number quantifications, RNA-seq, proteomic quantifications, and genome-wide CRISPR-Cas9 KO screen data that were made available by the DepMap data platform (<xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref>; <xref rid="btad381-B17" ref-type="bibr">Meyers <italic toggle="yes">et al.</italic> 2017</xref>, <xref rid="btad381-B10" ref-type="bibr">Ghandi <italic toggle="yes">et al.</italic> 2019</xref>, <xref rid="btad381-B19" ref-type="bibr">Nusinow <italic toggle="yes">et al.</italic> 2020</xref>) and predicts candidate GIs in three steps: (i) selecting control and mutant cancer cell lines; (ii) surveying mRNA and/or protein expression changes; and (iii) predicting and visualizing GIs (illustrated in <xref rid="btad381-F1" ref-type="fig">Fig. 1</xref> with a detailed version provided in <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S1A</xref>). Briefly, the first step is driven by a user-defined feature, such as a gene of interest (GOI). By default, when a GOI is provided, all pan-cancer cell lines with wildtype (WT) alleles and neutral copy number of the GOI are assigned to the control group, and lines with loss-of-function alterations in the GOI are assigned to one of the mutant subgroups, including homozygous deletion (HomDel), trans-heterozygous deletion, and heterozygous deletion groups (see <xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref> for details). Cell lines can also be selected by specific mutation, cancer type, or manual curation (<xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref>).</p>
      <fig position="float" id="btad381-F1">
        <label>Figure 1</label>
        <caption>
          <p>An overview of <italic toggle="yes">in silico</italic> GI screening and essentiality mapping using GRETTA. Top panel: A user defines a GOI and/or a cancer type to map GI or essentiality networks. When a cancer type is not defined, GRETTA defaults to a pan-cancer GI screen or essentiality mapping. Left panel: A three-step workflow to predict and visualize candidate GIs of a user-defined GOI in the defined cancer type. After cell lines are grouped into control or mutant groups, the user must select one mutant group based on gene and protein expression phenotypes. The genome-wide KO screen data for this user-selected mutant cell line group are then compared to those of the control group to predict lethal and alleviating GIs. Right panel: Pearson correlation analyses are performed between the KO effect scores of the GOI and each gene that was targeted in DepMap’s genome-wide screen (18 333 genes). The thresholds used to determine co-/antiessential genes are partly determined using inflection points of the ranked positive and negative coefficient curves. A detailed description of the workflow is provided in <xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref>. The DepMap data type processed at each step is illustrated in each subheading and noted in the legend. This figure was partly created with BioRender.com.</p>
        </caption>
        <graphic xlink:href="btad381f1" position="float"/>
      </fig>
      <p>The second step involves extracting DepMap mRNA and protein expression data (if available) and performing differential mRNA and protein expression analyses of the GOI between control cell lines and mutant cell lines (<xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref>). A mutant group with a significant reduction in mRNA or protein expression compared to the control group by Welch’s <italic toggle="yes">t</italic>-test is consistent with a potential reduction of GOI functions, and thus a user may select such a mutant cell line group for downstream analysis.</p>
      <p>Finally, candidate GIs are predicted by conducting differential lethality probability analyses, which identify a gene KO that results in opposing survival outcomes in the mutant cell lines and control cell lines. Mann–Whitney <italic toggle="yes">U</italic> tests are performed by extracting the lethality probabilities of each of the 18 333 genes that were targeted in the DepMap CRISPR-Cas9 KO screen and comparing the control and mutant cancer cell line groups. Optionally, at this step, a list of genes can be provided to perform a small-scale screen. GRETTA also generates an interaction score that is used to visualize candidate GIs and to rank them from most to least likely to be lethal or alleviating (<xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref>).</p>
    </sec>
    <sec>
      <title>2.2 Mapping essentiality networks</title>
      <p>GRETTA adapted a previously published Pearson correlation-based method for mapping essentiality between genes (<xref rid="btad381-B27" ref-type="bibr">Wang <italic toggle="yes">et al.</italic> 2017</xref>, <xref rid="btad381-B20" ref-type="bibr">Pan <italic toggle="yes">et al.</italic> 2018</xref>, <xref rid="btad381-B14" ref-type="bibr">Kim <italic toggle="yes">et al.</italic> 2019</xref>; illustrated in <xref rid="btad381-F1" ref-type="fig">Fig. 1</xref>, <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S1A</xref>; see <xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref> for detailed description). Briefly, the genome-wide CRISPR-Cas9 KO screen data from DepMap is used to calculate pan-cancer essentiality of a gene in the following steps. First, KO effect scores of GOIs (a user-defined input) are extracted from all screened cancer cell lines. Next, Pearson’s correlation coefficients and <italic toggle="yes">P</italic>-values are calculated between the KO effect scores of the GOIs and 18 333 genes screened in the dataset. Next, the inflection point of the ranked positive and negative coefficient score curves is calculated to determine a threshold to identify co-essential (positively correlated) and antiessential (negatively correlated) genes. Finally, a ranked correlation coefficient score is provided as an output and is used to visualize essentiality networks.</p>
    </sec>
  </sec>
  <sec>
    <title>3 Case study: predicting pan-cancer GIs and co-essentiality networks of <italic toggle="yes">ARID1A</italic></title>
    <p><italic toggle="yes">ARID1A</italic> is a member of the mammalian switch/sucrose non-fermentable (SWI/SNF) complex (<xref rid="btad381-B16" ref-type="bibr">Mashtalir <italic toggle="yes">et al.</italic> 2018</xref>) with a known SL GI to its paralog <italic toggle="yes">ARID1B</italic> (<xref rid="btad381-B13" ref-type="bibr">Helming <italic toggle="yes">et al.</italic> 2014</xref>). Rationalizing that this known SL interaction and complex association would serve as positive controls, we applied GRETTA to predict pan-cancer GIs and essentiality networks of <italic toggle="yes">ARID1A</italic>, expecting to replicate known interactors and co-essential genes, respectively. We identified an <italic toggle="yes">ARID1A</italic> WT control group and an <italic toggle="yes">ARID1A</italic> HomDel mutant group, consisting of 906 and 23 cell lines, respectively. The <italic toggle="yes">ARID1A</italic> HomDel mutant group showed significantly reduced <italic toggle="yes">ARID1A</italic> mRNA expression compared to the control group (Welch’s <italic toggle="yes">t</italic>-test <italic toggle="yes">P</italic> &lt;.05; <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S2A</xref> and <xref rid="sup1" ref-type="supplementary-material">B</xref> and <xref rid="sup1" ref-type="supplementary-material">Table S1A</xref> and <xref rid="sup1" ref-type="supplementary-material">B</xref>), consistent with potentially reduced ARID1A function. Using these two groups, we found that <italic toggle="yes">ARID1B</italic> was predicted to be the top lethal genetic interactor of <italic toggle="yes">ARID1A</italic> (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S2C</xref> and <xref rid="sup1" ref-type="supplementary-material">Table S1C</xref>), thus confirming the established SL GI between these two genes. Furthermore, a pan-cancer essentiality analysis of <italic toggle="yes">ARID1A</italic> revealed the expected top five list of co-essential genes that are known mSWI/SNF complex members, namely <italic toggle="yes">ARID1A, SMARCB1</italic>, <italic toggle="yes">SMARCE1</italic>, <italic toggle="yes">SMARCC1</italic>, and <italic toggle="yes">SS18</italic> (<xref rid="btad381-B16" ref-type="bibr">Mashtalir <italic toggle="yes">et al.</italic> 2018</xref>; <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S2D</xref> and <xref rid="sup1" ref-type="supplementary-material">Table S1D</xref>). GRETTA was thus able to recapitulate known GIs and co-essential networks of <italic toggle="yes">ARID1A</italic>.</p>
  </sec>
  <sec>
    <title>4 Discussion</title>
    <p>GRETTA was built to provide an easy-to-use method for mapping GI and essentiality networks. The R package requires only a basic understanding of the R programming language and we provide an easy-to-follow tutorial (<ext-link xlink:href="https://github.com/ytakemon/GRETTA" ext-link-type="uri">https://github.com/ytakemon/GRETTA</ext-link>). Using GRETTA, we replicated known GIs and essentiality networks of ARID1A, thus demonstrating how the tool can be used and ultimately applied to discover GI and essentiality networks of other GOI. We are currently aware of 365 visitors and 135 total unique installations of GRETTA and from this deduce that GRETTA is of interest to the wider research community.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>btad381_Supplementary_Data</label>
      <media xlink:href="btad381_supplementary_data.zip">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ack1">
    <title>Acknowledgements</title>
    <p>We would like to acknowledge the Broad Institute for generating and making their DepMap data platform available for the research community. We would like to thank Drs Anindya Dutta and Yoshiyuki Shibata at the University of Alabama at Birmingham Marnix E. Heersink School of Medicine for testing GRETTA and for the discussions that helped improve its documentation. We would also like to thank Richard Corbett at Canada’s Michael Smith Genome Sciences Centre for the discussion and guidance on containerizing the tool for reproducibility.</p>
  </ack>
  <sec>
    <title>Supplementary data</title>
    <p><xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> is available at <italic toggle="yes">Bioinformatics</italic> online.</p>
  </sec>
  <sec sec-type="COI-statement">
    <title>Conflict of interest</title>
    <p>None declared.</p>
  </sec>
  <sec>
    <title>Funding</title>
    <p>This work was supported by the Canadian Institutes of Health Research (CIHR; FDN-143288) and the Canada Research Chairs to M.A.M.; and the University of British Columbia (UBC) Four-year fellowships (6456, 6569), UBC International Student Award (4884), and UBC President’s Academic Excellence Initiative PhD Award (6817) to Y.T.</p>
  </sec>
  <sec sec-type="data-availability">
    <title>Data availability</title>
    <p>The GRETTA R package, data analyzed in this study (DepMap version 22Q2), and the code used to generate the supplementary figures and tables are publicly available as a tutorial provided on the GRETTA GitHub repository (<ext-link xlink:href="https://github.com/ytakemon/GRETTA" ext-link-type="uri">https://github.com/ytakemon/GRETTA</ext-link>). GRETTA has been archived with a citable DOI on Zenodo (<ext-link xlink:href="https://doi.org/10.5281/zenodo.6940757" ext-link-type="uri">https://doi.org/10.5281/zenodo.6940757</ext-link>) and a Singularity container has been made available on Sylabs (<ext-link xlink:href="https://cloud.sylabs.io/library/ytakemon/gretta/gretta" ext-link-type="uri">https://cloud.sylabs.io/library/ytakemon/gretta/gretta</ext-link>) to ensure reproducibility. GRETTA is shared under the GNU General Public License v3.0.</p>
  </sec>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="btad381-B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Behan</surname><given-names>FM</given-names></string-name>, <string-name><surname>Iorio</surname><given-names>F</given-names></string-name>, <string-name><surname>Picco</surname><given-names>G</given-names></string-name></person-group><etal>et al</etal><article-title>Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens</article-title>. <source>Nature</source><year>2019</year>;<volume>568</volume>:<fpage>511</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">30971826</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Benfatto</surname><given-names>S</given-names></string-name>, <string-name><surname>Serçin</surname><given-names>Ö</given-names></string-name>, <string-name><surname>Dejure</surname><given-names>FR</given-names></string-name></person-group><etal>et al</etal><article-title>Uncovering cancer vulnerabilities by machine learning prediction of synthetic lethality</article-title>. <source>Mol Cancer</source><year>2021</year>;<volume>20</volume>:<fpage>111</fpage>.<pub-id pub-id-type="pmid">34454516</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B4">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bryant</surname><given-names>HE</given-names></string-name>, <string-name><surname>Schultz</surname><given-names>N</given-names></string-name>, <string-name><surname>Thomas</surname><given-names>HD</given-names></string-name></person-group><etal>et al</etal><article-title>Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase</article-title>. <source>Nature</source><year>2005</year>;<volume>434</volume>:<fpage>913</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">15829966</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chiu</surname><given-names>Y-C</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>S</given-names></string-name>, <string-name><surname>Wang</surname><given-names>L-J</given-names></string-name></person-group><etal>et al</etal><article-title>Predicting and characterizing a cancer dependency map of tumors with deep learning</article-title>. <source>Sci Adv</source><year>2021</year>;<volume>7</volume>:eabh1275.</mixed-citation>
    </ref>
    <ref id="btad381-B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>De Kegel</surname><given-names>B</given-names></string-name>, <string-name><surname>Quinn</surname><given-names>N</given-names></string-name>, <string-name><surname>Thompson</surname><given-names>NA</given-names></string-name></person-group><etal>et al</etal><article-title>Comprehensive prediction of robust synthetic lethality between paralog pairs in cancer cell lines</article-title>. <source>Cell Syst</source><year>2021</year>;<volume>12</volume>:<fpage>1144</fpage>–<lpage>59.e6</lpage>. <pub-id pub-id-type="doi">10.1016/j.cels.2021.08.006</pub-id>.<pub-id pub-id-type="pmid">34529928</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B9">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Farmer</surname><given-names>H</given-names></string-name>, <string-name><surname>McCabe</surname><given-names>N</given-names></string-name>, <string-name><surname>Lord</surname><given-names>CJ</given-names></string-name></person-group><etal>et al</etal><article-title>Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</article-title>. <source>Nature</source><year>2005</year>;<volume>434</volume>:<fpage>917</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">15829967</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B21">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Geethakumari</surname><given-names>PR</given-names></string-name>, <string-name><surname>Schiewer</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Knudsen</surname><given-names>KE</given-names></string-name></person-group><etal>et al</etal><article-title>PARP inhibitors in prostate cancer</article-title>. <source>Curr Treat Options Oncol</source><year>2017</year>;<volume>18</volume>:<fpage>37</fpage>.<pub-id pub-id-type="pmid">28540598</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ghandi</surname><given-names>M</given-names></string-name>, <string-name><surname>Huang</surname><given-names>FW</given-names></string-name>, <string-name><surname>Jané-Valbuena</surname><given-names>J</given-names></string-name></person-group><etal>et al</etal><article-title>Next-generation characterization of the cancer cell line encyclopedia</article-title>. <source>Nature</source><year>2019</year>;<volume>569</volume>:<fpage>503</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">31068700</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hart</surname><given-names>T</given-names></string-name>, <string-name><surname>Chandrashekhar</surname><given-names>M</given-names></string-name>, <string-name><surname>Aregger</surname><given-names>M</given-names></string-name></person-group><etal>et al</etal><article-title>High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities</article-title>. <source>Cell</source><year>2015</year>;<volume>163</volume>:<fpage>1515</fpage>–<lpage>26</lpage>.<pub-id pub-id-type="pmid">26627737</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Helming</surname><given-names>KC</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>BG</given-names></string-name></person-group><etal>et al</etal><article-title>ARID1B is a specific vulnerability in ARID1A-mutant cancers</article-title>. <source>Nat Med</source><year>2014</year>;<volume>20</volume>:<fpage>251</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">24562383</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B14">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname><given-names>E</given-names></string-name>, <string-name><surname>Dede</surname><given-names>M</given-names></string-name>, <string-name><surname>Lenoir</surname><given-names>WF</given-names></string-name></person-group><etal>et al</etal><article-title>A network of human functional gene interactions from knockout fitness screens in cancer cells</article-title>. <source>Life Sci Alliance</source><year>2019</year>;<volume>2</volume>:<fpage>e201800278</fpage>.<pub-id pub-id-type="pmid">30979825</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B15">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mani</surname><given-names>R</given-names></string-name>, <string-name><surname>St Onge</surname><given-names>RP</given-names></string-name>, <string-name><surname>Hartman</surname><given-names>JL</given-names></string-name></person-group><etal>et al</etal><article-title>Defining genetic interaction</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2008</year>;<volume>105</volume>:<fpage>3461</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">18305163</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mashtalir</surname><given-names>N</given-names></string-name>, <string-name><surname>D'Avino</surname><given-names>AR</given-names></string-name>, <string-name><surname>Michel</surname><given-names>BC</given-names></string-name></person-group><etal>et al</etal><article-title>Modular organization and assembly of SWI/SNF family chromatin remodeling complexes</article-title>. <source>Cell</source><year>2018</year>;<volume>175</volume>:<fpage>1272</fpage>–<lpage>88.e20</lpage>.<pub-id pub-id-type="pmid">30343899</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B17">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Meyers</surname><given-names>RM</given-names></string-name>, <string-name><surname>Bryan</surname><given-names>JG</given-names></string-name>, <string-name><surname>McFarland</surname><given-names>JM</given-names></string-name></person-group><etal>et al</etal><article-title>Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells</article-title>. <source>Nat Genet</source><year>2017</year>;<volume>49</volume>:<fpage>1779</fpage>–<lpage>84</lpage>.<pub-id pub-id-type="pmid">29083409</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B18">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mirza</surname><given-names>MR</given-names></string-name>, <string-name><surname>Pignata</surname><given-names>S</given-names></string-name>, <string-name><surname>Ledermann</surname><given-names>JA</given-names></string-name></person-group><etal>et al</etal><article-title>Latest clinical evidence and further development of PARP inhibitors in ovarian cancer</article-title>. <source>Ann Oncol</source><year>2018</year>;<volume>29</volume>:<fpage>1366</fpage>–<lpage>76</lpage>.<pub-id pub-id-type="pmid">29750420</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B19">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nusinow</surname><given-names>DP</given-names></string-name>, <string-name><surname>Szpyt</surname><given-names>J</given-names></string-name>, <string-name><surname>Ghandi</surname><given-names>M</given-names></string-name></person-group><etal>et al</etal><article-title>Quantitative proteomics of the cancer cell line encyclopedia</article-title>. <source>Cell</source><year>2020</year>;<volume>180</volume>:<fpage>387</fpage>–<lpage>402.e16</lpage>.<pub-id pub-id-type="pmid">31978347</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B20">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pan</surname><given-names>J</given-names></string-name>, <string-name><surname>Meyers</surname><given-names>RM</given-names></string-name>, <string-name><surname>Michel</surname><given-names>BC</given-names></string-name></person-group><etal>et al</etal><article-title>Interrogation of mammalian protein complex structure, function, and membership using Genome-Scale fitness screens</article-title>. <source>Cell Syst</source><year>2018</year>;<volume>6</volume>:<fpage>555</fpage>–<lpage>68.e7</lpage>.<pub-id pub-id-type="pmid">29778836</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B22">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Robson</surname><given-names>M</given-names></string-name>, <string-name><surname>Goessl</surname><given-names>C</given-names></string-name>, <string-name><surname>Domchek</surname><given-names>S</given-names></string-name></person-group><etal>et al</etal><article-title>Olaparib for metastatic germline BRCA-mutated breast cancer</article-title>. <source>N Engl J Med</source><year>2017</year>;<volume>377</volume>:<fpage>1792</fpage>–<lpage>3</lpage>.</mixed-citation>
    </ref>
    <ref id="btad381-B23">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Robson</surname><given-names>ME</given-names></string-name>, <string-name><surname>Tung</surname><given-names>N</given-names></string-name>, <string-name><surname>Conte</surname><given-names>P</given-names></string-name></person-group><etal>et al</etal><article-title>OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer</article-title>. <source>Ann Oncol</source><year>2019</year>;<volume>30</volume>:<fpage>558</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="pmid">30689707</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B24">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shalem</surname><given-names>O</given-names></string-name>, <string-name><surname>Sanjana</surname><given-names>NE</given-names></string-name>, <string-name><surname>Hartenian</surname><given-names>E</given-names></string-name></person-group><etal>et al</etal><article-title>Genome-scale CRISPR-Cas9 knockout screening in human cells</article-title>. <source>Science</source><year>2014</year>;<volume>343</volume>:<fpage>84</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">24336571</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B25">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Takemon</surname><given-names>Y</given-names></string-name>, <string-name><surname>LeBlanc</surname><given-names>VG</given-names></string-name>, <string-name><surname>Song</surname><given-names>J</given-names></string-name></person-group><etal>et al</etal><article-title>Multi-omic analysis of CIC’s functional networks reveals novel interaction partners and a potential role in mitotic fidelity</article-title>. <source>Cancers</source><year>2023</year>;<volume>15</volume>:<fpage>2805</fpage>.</mixed-citation>
    </ref>
    <ref id="btad381-B26">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wainberg</surname><given-names>M</given-names></string-name>, <string-name><surname>Kamber</surname><given-names>RA</given-names></string-name>, <string-name><surname>Balsubramani</surname><given-names>A</given-names></string-name></person-group><etal>et al</etal><article-title>A genome-wide atlas of co-essential modules assigns function to uncharacterized genes</article-title>. <source>Nat Genet</source><year>2021</year>;<volume>53</volume>:<fpage>638</fpage>–<lpage>49</lpage>.<pub-id pub-id-type="pmid">33859415</pub-id></mixed-citation>
    </ref>
    <ref id="btad381-B27">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>T</given-names></string-name>, <string-name><surname>Yu</surname><given-names>H</given-names></string-name>, <string-name><surname>Hughes</surname><given-names>NW</given-names></string-name></person-group><etal>et al</etal><article-title>Gene essentiality profiling reveals gene networks and synthetic lethal interactions with oncogenic ras</article-title>. <source>Cell</source><year>2017</year>;<volume>168</volume>:<fpage>890</fpage>–<lpage>903.e15</lpage>.<pub-id pub-id-type="pmid">28162770</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
